King's Research Portal

DOI:

[10.1111/cea.13111](https://doi.org/10.1111/cea.13111)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Brough, H. A., Kull, I., Richards, K., Hallner, E., Söderhäll, C., Douiri, A., Penagos, M., Melén, E., Bergström, A., Turcanu, V., Wickman, M., & Lack, G. (2018). Environmental peanut exposure increases the risk of peanut sensitization in high risk children. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology*, 48(5), 586-593. <https://doi.org/10.1111/cea.13111>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Environmental peanut exposure increases the risk of peanut sensitization in high risk children

Journal:	<i>Clinical and Experimental Allergy</i>
Manuscript ID	CEA-2016-0458.R1
Manuscript Type:	Original Article-Epidemiology of Allergic Disease
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Brough, Helen; NHS, Paediatrics; Guy's and Saint Thomas' NHS Foundation Trust, Childrens Allergy Service</p> <p>Kull, Inger; Karolinska Institutet, Department of Clinical research and Education; Sachs Children and Youth hospital, Paediatric allergy</p> <p>Makinson, Kerry; Paediatric Allergy, Department of asthma, allergy and respiratory Science, Division of Allergy and Lung Biology, Kings College London</p> <p>Hallner, Eva; Karolinska Institutet, Institute of Environmental Medicine</p> <p>Söderhäll, Cilla; Karolinska Institutet, Biosciences and Nutrition; Karolinska Institutet, Department of Women's and Children's Health</p> <p>Douiri, Abdel; King's College, Department of Medical Statistics</p> <p>Penagos, Martin; MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, Department of asthma, Allergy and Respiratory Science</p> <p>Melen, Erik; Karolinska Institutet, Institute of Environmental Medicine</p> <p>Bergstrom, Anna; Karolinska Institutet, Institute of Environmental Medicine</p> <p>Turcanu, Victor; MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, Department of Asthma, Allergy and Respiratory Science</p> <p>Wickman, Magnus; Karolinska Institutet, Environmental Health</p> <p>Lack, Gideon; Kings College London, Paediatric Unit, Department of Medicine; MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, Department of Asthma, Allergy and Respiratory Science</p>
Keywords:	food allergy, IgE, immunologic tests
Additional Keywords:	peanut exposure, FLG mutation, peanut sensitization

Environmental peanut exposure increases the risk of peanut sensitization in high risk children

Helen A. Brough FRCPCH PhD*,^{1,2} Inger Kull PhD*,^{3,4,5} Kerry Makinson MSc,¹ Eva Hallner,³ B Cilla Söderhäll PhD,^{6,7, 9} Abdel Douiri PhD,⁸ Martin Penagos MD MSc,¹ Erik Melén,^{3,5} Anna Bergström,^{3,7} Victor Turcanu PhD,¹ Magnus Wickman MD PhD**,³ Gideon Lack MD FRCPCH**,^{1,2}

¹ Paediatric Allergy, Department of Asthma, Allergy and Respiratory Science, Division of Asthma Allergy and Lung Biology, MRC & Asthma UK Centre for the Allergic Mechanisms of Asthma, King's College London, Guys' Hospital, London, SE1 9RT, UK

² Children's Allergy Service, Guy's and St. Thomas's NHS Foundation Trust, Westminster Bridge Rd, London SE1 7EH.

³ Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Centre for Occupational and Environmental Medicine, Stockholm County Council, Stockholm, Sweden

⁴ Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden

⁵ Sachs' Children's Hospital, Södersjukhuset, Stockholm, Sweden

⁶ Department of Biosciences and Nutrition, Karolinska Institutet, 141 83 Stockholm, Sweden

⁹ Department of Women's and Children's Health, Karolinska Institutet, 171 77 Stockholm, Sweden

⁷ Centre of Allergy Research, Karolinska Institutet, Stockholm, Sweden

⁸ Department of Medical Statistics, Public Health School of Medicine, King's College London, Guys' Hospital, London, SE1 9RT, UK

* These authors contributed equally to the manuscript and are joint first authors.

**These authors contributed equally to the manuscript and are joint senior authors.

25 **Word count:** 2802

26 **Short Title:** Environmental peanut exposure and peanut sensitization in BAMSE

For Peer Review

Abstract

Background: High household peanut consumption is associated with the development of peanut allergy, especially when peanut allergic cases are compared against atopic controls; thus environmental peanut exposure (EPE) may be a risk factor for peanut sensitization and allergy. In this study we explored the relationship between EPE and peanut sensitization in a population based cohort.

Methods: Maternal bed-dust was collected postnatally and EPE was quantified using a polyclonal peanut ELISA. Peanut sensitization was assessed by peanut specific IgE and peanut protein allergen molecules (PAM) (Ara h 1, 2 or 3 ≥ 0.35 kU/L). Initial nested case control analysis was performed (n=411) followed by whole cohort analysis (n=1878).

Results: There was a significant association between EPE around birth and peanut specific IgE at age 4 years (OR=1.41 95% CI:1.05-1.90, and peanut PAM sensitization at age 8 years (OR=2.11 95% CI:1.38-3.22) compared against controls matched for gender and parental atopy; *FLG* loss-of-function mutations, egg sensitization at age 4 years, infantile eczema and allergic rhinitis were significantly associated with peanut sensitization; however, there was no significant interaction with EPE. When the whole BAMSE cohort was assessed, EPE was no longer associated with peanut sensitization; however, EPE was associated with peanut PAM sensitization when compared against egg-sensitized peanut-tolerant controls adjusted odds ratio of 1.56 per unit EPE (95% CI:1.14-2.12).

Conclusions: EPE was associated with an increased risk of peanut specific IgE and peanut PAM sensitization at 8 years of age when comparing peanut sensitized cases against atopic controls (egg sensitized children or children matched for parental atopy).

Abstract word count: 251

Key words: BAMSE, egg sensitization, environmental peanut exposure, *FLG* mutation, infantile eczema peanut sensitization

52 Funding

53 The research was funded/supported by Action Medical Research (S/P/4529) and by the National
54 Institute for Health Research (NIHR) Clinical Research Facility at Guy's & St Thomas' NHS
55 Foundation Trust and NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS
56 Foundation Trust and King's College London. The views expressed are those of the author(s) and
57 not necessarily those of the NHS, the NIHR or the Department of Health. The BAMSE study was
58 funded by the Swedish Research Council, the Stockholm County Council, the Swedish Research
59 Council for Health, Working life, and Welfare the Swedish Asthma and Allergy Foundation, the
60 Swedish Heart and Lung Foundation, and the Gillbergiska Foundation.

61 Abbreviations

62 AIC: Akaike information criterion
63 Ara h: *Arachis hypogaea*
64 BAMSE: Children/'Barn' Allergy Milieu Stockholm Epidemiological project
65 CI: confidence intervals
66 EPE: environmental peanut exposure
67 *FLG*: gene encoding the protein filaggrin
68 GEE: Generalized Estimating Equations
69 ISAAC: International Study of Asthma and Allergies in Childhood
70 IQR: Interquartile range
71 PAM: protein allergen molecule
72 QIC: Quasi Likelihood Independence models criterion

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Peanut allergy has increased,^(1;2) is a leading cause of anaphylaxis in food allergy⁽³⁾ and has a significant impact on quality of life for the child and their family.^(4;5) Most children react on first known oral exposure to peanut; thus sensitization must be occurring earlier.^(6;7) Understanding the way children become sensitized to peanut is therefore imperative in order to prevent this condition. Observational⁽⁸⁾ and animal work⁽⁹⁾ suggests that epicutaneous peanut exposure and early onset severe eczema may play an important role in peanut sensitization.

Epicutaneous exposure may be the route that peanut levels in dust sensitize a child in early life, particularly if the skin barrier is broken through eczema or specific genetic mutations associated with skin barrier dysfunction (e.g. filaggrin (*FLG*) mutations or eczema). We have recently shown in the Manchester Asthma and Allergy Study (MAAS) and Consortium of Food Allergy Research (CoFAR) cohort that *FLG* loss-of-function mutations and eczema severity respectively can increase the impact of early EPE on peanut sensitization and allergy.^(10;11)

A dose response relationship has also been demonstrated between household peanut consumption (used as an indirect marker for environmental peanut exposure: EPE) and the risk of developing peanut allergy in young children.⁽¹²⁾ They compared household peanut consumption in peanut allergic individuals against children who were at high risk of developing peanut allergy (due to the presence of egg allergy) but had not developed peanut allergy. Household peanut consumption was ten times higher in households with infants with peanut allergy versus children with egg allergy without peanut allergy but was only 3 times higher in non atopic controls, highlighting that household peanut consumption was more likely to be associated with peanut allergy in high risk children.⁽¹²⁾ Peanut antigen in the infant's bed-dust and play-area-dust is highly positively correlated with household peanut consumption and stimulates basophils from peanut allergic children, thus has the potential to also sensitize individuals.⁽¹³⁾

98

99 Peanut sensitization (specific IgE $\geq$ 0.35kU/L) is present in up to 10% of children and protein allergen
100 molecule (PAM) analysis of the seed storage proteins in peanut (Ara h 1, 2 and 3) has been shown
101 to improve the specificity and sensitivity of diagnosing peanut allergy.^(14;15) In BAMSE, children with
102 IgE reactivity to Ara h 1, 2 or 3 at age 8 years (but not Ara h 8) reported peanut allergic symptoms in
103 87% of cases, whereas children with IgE reactivity exclusively to Ara h 8 reported peanut allergic
104 symptoms in only 17% of cases which were also milder.⁽¹⁶⁾ Sweden has high levels of birch pollen
105 sensitization which explains the Bet v 1 in-vitro cross-reactivity with peanut Ara h 8,^(16;17) thus, in
106 this study we differentiated between primary peanut sensitization (IgE reactivity to Ara h 1, 2 or 3)
107 and pollen cross-reactivity (IgE reactivity to Ara h 8).

108 This study aimed to assess whether EPE (as defined by peanut protein levels in household dust) is
109 a risk factor for the development of peanut sensitization. The analysis was done in two steps; firstly
110 among high risk children, in a nested cases analysis and secondly among the whole studied
111 population (a cohort analysis). Given previous findings we also wanted to ascertain the modifying
112 effects of *FLG* loss-of-function mutations, infantile eczema and preceding egg sensitization.

113

Methods

The BAMSE study is an unselected Swedish population birth cohort. The design and methodology are described elsewhere.⁽¹⁸⁾ In brief 4089 unselected newborn children were recruited from 1994-1996 and have been evaluated for various health conditions over time. No intervention was performed. The BAMSE study obtained ethical approval for environmental sampling of dust.

Demographics

Serum specific IgE to peanut (ImmunoCAP system, ThermoFisher, Sweden) was measured at 4 and 8 years and children were defined as 'peanut sIgE sensitized' if peanut specific IgE was $\geq 0.35\text{kU/L}$. Peanut allergen molecules (PAM) were assessed at 8 years (ImmunoCAP system, ThermoFisher, Sweden) and children were considered to be peanut PAM sensitized if *Ara h 1, 2 or 3* was $\geq 0.35\text{kU/L}$ and not peanut PAM sensitized if *Ara h 1, 2 and 3* were $< 0.35\text{kU/L}$ or peanut sIgE was $< 0.35\text{kU/L}$ at 8 years (where no peanut PAM available). Children with positive peanut specific IgE at 8 years of age but with no available PAM analysis were excluded from this analysis. Egg sensitization was defined as egg specific IgE $\geq 0.35\text{kU/L}$ at 4 years of age.

Parental atopy was defined as a doctor's diagnosis of asthma and prescription of asthma medication and/or a doctor's diagnosis of hay fever in combination with furred pets- and/or pollen allergy at the time of questionnaire.

Genotyping was performed for *FLG* mutations common in Scandinavia by using TaqMan allelic discrimination assays for R501X and R2447X and matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry for 2282del4. Children with a mutation in any of these positions were classified as having a loss-of function mutation.

A reported history of infantile eczema was assessed by questionnaire and was defined as dry skin, itchy rashes for 2 weeks or more and age specific localization (face or arms/legs extension surfaces or arms/legs flexures or wrists/ankles flexures) and/or doctor's diagnosis of eczema during the first year of life.

Ethnicity was based on where the parents were born. Allergic rhinitis at 4 and 8 years was assessed using International Study of Asthma and Allergies in Childhood (ISAAC) validated questionnaires, and was defined as persistent rhinitis without a common cold the last 12 months before 4 and 8 years respectively.⁽¹⁹⁾

Dust collection methodology

Dust samples were collected at a median of 2 months of age from the mother's mattress. The mother's mattress was vacuumed for 2.5 minutes with a small disposable filter bag (Allergy Control Products Inc. Ridgefield CT, USA) inserted in the front hose of the vacuum. The dust containing filter bags were sealed in plastic bags and stored at -20°C. Dust samples were sieved and fine dust was weighed and extracted in proportional volumes of extraction solution as previously described.⁽²⁰⁾ Peanut protein in dust was determined using the Veratox polyclonal ELISA against whole peanut protein (Neogen Corporation, Lansing, MI, USA). The lower limit of quantitation (LLQ) of the assay was defined as 100ng/ml and samples below this value were defined as 50ng/ml (LLQ/2).⁽²¹⁾ Results were converted from ng/ml into µg peanut protein/gram dust. Due to batch to batch variability of the Veratox ELISA results were batch corrected prior to being entered into the final statistical analysis.

Statistical analysis

Data was entered into an SPSS (SPSS 19.0; SPSS Inc, Chicago, IL, USA) and STATA spreadsheet (Timberlake Consultants Ltd London, UK) for the purpose of analysis. Peanut protein levels in dust (µg/gram) underwent natural log transformation. Initial nested case control analysis was performed with peanut sIgE sensitized cases at 4 years of age matched for gender and parental atopy with a 2:1 control (n=274) to case (n=137) matching. Children with peanut PAM sensitization defined by Ara h 1, 2 or 3 ≥ 0.35 kU/L at 8 years of age were also matched against controls at age 8 years matched for gender and parental atopy with a 2:1 ratio of controls (n=130) to cases (n=65). Conditional logistic regression (incorporating matching) was performed for the case control analysis

1
2
3 167 using robust standard error for peanut sIgE sensitization at 4 years and peanut PAM sensitization at
4
5 168 age 8 years.
6
7
8 169 Subsequently analysis was performed for the relationship between early EPE and peanut
9
10 170 sensitization in all children from the BAMSE cohort with available postnatal maternal bed-dust and
11
12 171 *FLG* genotyping (n=1878). Logistic regression analysis was performed for peanut PAM sensitization
13
14 172 at 8 years of age. Factors associated with peanut sIgE sensitization were assessed using
15
16 173 Generalized Estimating Equations (GEE) with an exchangeable working correlation matrix to
17
18 174 account for repeated measures within individuals at 4 and 8 years. Univariate followed by
19
20 175 multivariate regression analysis was performed including EPE, *FLG* loss-of-function mutations,
21
22 176 infantile eczema and egg sensitization at 4 years of age plus other covariates significantly
23
24 177 association with peanut sensitization ($P \leq .05$) which also improved the quality of fit of the multivariate
25
26 178 model using the Akaike information criterion (AIC) for logistic regression and the Quasi Likelihood
27
28 179 Independence models criterion (QIC) for GEE analyses.
29
30
31 180 Where the *FLG* mutation covariate was entered into the statistical model, participants with missing
32
33 181 ethnicity data (35/1878=1.9%) and non-caucasians (165/1842=8.8%) were excluded as distinct *FLG*
34
35 182 loss-of-function mutations are present in different populations and the *FLG* loss-of-function
36
37 183 mutations assessed in this study have only been associated with eczema in Caucasian European
38
39 184 populations ^(22;23) Peanut levels in dust ($\mu\text{g/g}$) were compared between groups using the Mann-
40
41 185 Whitney U test. Proportions between groups (e.g. infantile eczema and *FLG* mutations) were
42
43 186 compared using Pearson chi-squared. Statistical significance was assessed at $P < .05$.
44
45
46 187
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

Details of demographics and clinical characteristics included on this study are described in Table E1. Median peanut protein [IQR] in dust was 4.07 µg/gram [1.58, 11.86]. Peanut extract sIgE sensitization was 6.6% at 4 years (n=103/1572) and 8.6% at 8 years (n=161/1876). Peanut PAM sensitization at 8 years was 4.1% (n=75/1854), of which 74/75 (99%) had Ara h 2 ≥0.35kU/l. We first performed a nested case control analysis, and based on positive findings for this subsequently proceeded to then analyse the whole BAMSE cohort.

Nested case control analysis for peanut sIgE and PAM sensitization

We compared peanut sensitized children against children without peanut sensitization matched for gender and parental atopy as described in the statistical methods; EPE was a risk factor for both peanut extract sIgE sensitization at 4 years and peanut PAM sensitization at 8 years with a 23% and 29% increased risk of peanut sensitization per natural log (*ln*) unit increase in EPE respectively (Table I). In children who were peanut extract sIgE sensitized but not peanut PAM sensitized, there was only borderline significance towards an association between EPE and peanut sensitization (OR=1.20, 95% CI: 0.97-1.48).

Differential relationship between EPE and primary peanut PAM sensitization and non-clinically significant peanut sensitization is displayed in Figure 1. Median peanut protein in dust was higher in peanut extract sIgE sensitized children (3.39 µg/g, IQR 1.41-11.01, n=137) than non-peanut extract sIgE sensitized controls (2.28 µg/g, IQR 0.88-5.14, n=274) (*P*<.01); and higher in peanut PAM sensitized children (4.64 µg/g, IQR 1.58-12.77, n=65) than non-peanut PAM sensitized controls (2.24 µg/g, IQR 0.88-4.74, n=130) (*P*<.01).

On multivariate conditional logistic regression analysis, EPE was significantly associated with peanut specific IgE and peanut PAM sensitization with a 1.41- and 2.1-fold increased risk per unit increase EPE respectively (Table II).

Infantile eczema and egg sensitization were both significantly associated with peanut extract sIgE and PAM sensitization (Table II). *FLG* loss-of function mutations increased the risk of peanut

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

specific IgE 3.78-fold and peanut PAM sensitization 7.33-fold. Allergic rhinitis at age 4 and 8 years was associated with both peanut specific IgE at age 4 years and peanut PAM sensitization at age 8 years in the multivariate analysis. The number of biological siblings, duration of exclusive and total breastfeeding and maternal age at baseline were not risk factors for peanut sensitization. There was no significant interaction between EPE and either infantile eczema, egg sensitization or *FLG* loss-of-function mutations on peanut PAM sensitization (data not shown).

Whole cohort analysis for peanut sIgE and PAM sensitization

In a second step following positive findings obtained on case control analysis, analysis was performed for the relationship between early EPE and peanut sensitization in all children from the BAMSE cohort with available postnatal maternal bed-dust and *FLG* genotyping (n=1878). On both univariate (Table III) and multivariate analysis (Table IV) infantile eczema, egg sensitization, *FLG* loss-of function mutation and allergic rhinitis at age 8 years were associated with peanut extract sIgE at age 4 and 8 years. For PAM sensitization at age 8 significant associations were also seen on univariate (Table III) and multivariate analysis (Table IV) for infantile eczema, egg sensitization and allergic rhinitis at age 8 years. However, EPE was no longer associated with peanut sensitization. There was no interaction between EPE and *FLG* mutations, infantile eczema, egg sensitization or parental atopy on peanut sensitization.

Subgroup analysis of peanut PAM sensitization against egg sensitized non peanut allergic individuals

On subgroup analysis we compared peanut PAM sensitized children (n=75) against children who were sensitized to egg (sIgE≥0.35kU/L at age 4 years) but did not go on to develop peanut PAM sensitization (n=59). EPE was a risk factor for peanut PAM sensitization on both univariate (OR=1.33 95% CI:1.01-1.74, *P*<.05, n=134) (Table V) and multivariate analysis (OR=1.56, 95%

239 CI:1.14-2.12, $P<.01$, $n=132$, AIC: 331) adjusting for allergic rhinitis at age 8 years and infantile
240 eczema. Peanut levels in household dust were also significantly higher in peanut PAM sensitized
241 children (median 4.79 μ g/g, IQR 1.63-12.00) versus egg sensitized, non-peanut PAM sensitized
242 children (median 2.35 μ g/g, IQR 1.23-6.15) ($P=.03$).

243 We assessed the impact of EPE on peanut sensitization when using other high-risk groups of
244 children who did not become peanut sensitized (*FLG* mutations, infantile eczema, parental atopy)
245 and there was no significant association.

246

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

In the prospective birth cohort BAMSE, there was an exposure-response relationship between EPE (quantified using peanut protein levels from maternal mattress-dust postnatally) and peanut PAM sensitization (Ara h 1, 2 or 3 $\geq 0.35\text{kU/L}$) among high risk children (in a nested cases analysis). When all children in the whole studied population were assessed, there was no association between EPE and peanut sensitization; however, on subgroup analysis there was an exposure-response relationship between EPE and peanut PAM sensitization when compared against high risk egg sensitized children.

This supports the findings by Fox et al. where household peanut consumption during the first year of life (as an indirect marker of EPE) was higher in peanut allergic cases than in egg allergic controls.⁽¹²⁾ The exposure-response relationship between EPE and PS (when compared against atopic controls) was stronger between EPE and peanut CRD sensitization (Ara h 1,2 or 3 $\geq 0.35\text{kU/L}$) than between EPE and non-clinically relevant PS (peanut sIgE $\geq 0.35\text{kU/L}$ but negative results for Ara h 1,2 or 3 $< 0.35\text{kU/L}$) (Figure 1). The association between household peanut consumption and peanut sensitization was also found in a study by Garcia-Boyano et al.⁽²⁴⁾ and supports the concept that EPE increases the risk of clinically relevant peanut sensitization.

In other cohorts we have shown a synergistic effect between EPE and markers of an impaired skin barrier (infantile eczema and *FLG* loss-of-function mutations) on peanut sensitization and allergy.^(11;25) Although in BAMSE we did not find significant interactions between EPE and *FLG* mutations or infantile eczema on peanut sensitization, we did show on subgroup analysis that early EPE has more impact in children with certain risk factors for the development of peanut sensitization (such as parental atopy or egg sensitization) than children without these risk factors. The BAMSE cohort is relatively non-atopic, being from the general population in Sweden, which may have contributed to lower strength of associations between EPE and atopic markers.

Infantile eczema was one of the most important risk factors for peanut sensitization in BAMSE; this association has been cited in numerous studies.^(8;26) *FLG* loss-of-function mutations were less important than infantile eczema in predicting the development of peanut sensitization, and *FLG* mutations became more important if infantile eczema was not included in the regression model. Previous studies have found that children that carry a *FLG* mutation have an increased risk of peanut allergy even after adjusting for eczema.⁽²⁷⁾ In this study eczema seemed to be the overriding factor for peanut sensitization; however, it should be noted that *FLG* mutations were quite low in BAMSE (7.14%) in comparison with other population-based cohorts.^(22;27) Egg sensitization was highly associated with peanut sensitization; which has previously been shown in numerous cohort studies,^(25;28;29) it may be that egg sensitization shows a predisposition to mount allergic antibodies to other allergens as egg allergy is highly associated with the development of other food allergies, asthma and aeroallergen sensitization.^(30;31) Observational studies have shown that in children with severe, early onset eczema, up to 50% are sensitized to egg,⁽²⁶⁾ thus egg sensitization may be a marker of eczema severity. Limitations of this study included the lack of diagnostic food challenges to determine peanut allergy; however, peanut PAM sensitization has been shown to be a much more accurate predictor of clinically confirmed peanut allergy than peanut specific IgE.^(32;33) Caucasian ethnicity was defined as being born in Sweden as between 1994-1996 (when the BAMSE cohort commenced), most participants born in Sweden would have been of Northern European descent. In addition participants from Finland, Greece or Eastern Europe who were not born in Sweden were also defined as Caucasian.⁽³⁴⁾ Findings on case control analysis could not be replicated on whole cohort analysis, therefore these findings need to be confirmed in other population based cohorts. Strength of the present study includes the population based design and relatively high number of study participants.

Conclusion

In summary, although EPE did not increase the risk of peanut sensitization in children who did not already have atopic risk factors, the findings from the BAMSE cohort support the hypothesis that in specific high risk groups, peanut levels in dust around the time of birth may pose a risk for later

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

302 peanut sensitization. Further prospective studies are needed to confirm these findings in other
303 populations.

304
305 **Acknowledgement**

306 We wish to thanks Dr Alick Stephens for his assistance in the BAMSE dust analysis. The authors
307 thank all children and their parents in the BAMSE cohort
308

For Peer Review

References

- (1) Venter C, Hasan AS, Grundy J, Pereira B, Bernie CC, Voigt K et al. Time trends in the prevalence of peanut allergy: three cohorts of children from the same geographical location in the UK. *Allergy* 2010; 65(1):103-8.
- (2) Sicherer SH, Munoz-Furlong A, Godbold JH, Sampson HA. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. *J Allergy Clin Immunol* 2010; 125(6):1322-6.
- (3) Bock SA, Munoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. *J Allergy Clin Immunol* 2007; 119(4):1016-8.
- (4) Avery NJ, King RM, Knight S, Hourihane JO'B. Assessment of quality of life in children with peanut allergy. *Pediatr Allergy Immunol* 2003;5:378-82.
- (5) King RM, Knibb RC, Hourihane JO. Impact of peanut allergy on quality of life, stress and anxiety in the family. *Allergy* 2009; 64(3):461-8.
- (6) Hourihane JO'B, Kilburn SA, Dean P, Warner JO. Clinical characteristics of peanut allergy. *Clin Exp Allergy* 1997; 27(6):634-9.
- (7) Monti G, Muratore MC, Peltran A, Bonfante G, Silvestro L, Oggero R et al. High incidence of adverse reactions to egg challenge on first known exposure in young atopic dermatitis children: predictive value of skin prick test and radioallergosorbent test to egg proteins. *Clin Exp Allergy* 2002; 32(10):1515-9.
- (8) Lack G, Fox D, Northstone K, Golding J, Avon Longitudinal Study of Parents and Children Study Team. Factors associated with the development of peanut allergy in childhood. *N Engl J Med* 2003; 348(11):977-85.
- (9) Strid J, Hourihane J, Kimber I, Callard R, Strobel S. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. *Eur J Immunol* 2004; 34(8):2100-9.
- (10) Brough HA, Liu AH, Sicherer S, Makinson K, Douiri A, Brown SJ et al. Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy. *J Allergy Clin Immunol* 2015; 135(1):164-70.
- (11) Brough H.A., Simpson A., Makinson K., Sara B., Douiri A., Belgrave D. et al. Peanut allergy: Impact of environmental peanut exposure in children with filaggrin loss-of-function mutations. *J Allergy Clin Immunol* 2014; 134:867-75.
- (12) Fox AT, Sasieni P, Du Toit G, Syed H, Lack G. Household peanut consumption as a risk factor for the development of peanut allergy. *J Allergy Clin Immunol* 2009; 123(2):417-23.
- (13) Brough HA, Santos A, Makinson K, Penagos M, Stephens AC, Fox AT et al. Peanut protein in household dust is related to household peanut consumption and is biologically active. *J Allergy Clin Immunol* 2013; 132(3):630-8.
- (14) Nicolaou N, Murray C, Belgrave D, Poorafshar M, Simpson A, Custovic A. Quantification of specific IgE to whole peanut extract and peanut components in prediction of peanut allergy. *J Allergy Clin Immunol* 2011; 127(3):684-5.

1
2
3 349 (15) Dang TD, Tang M, Choo S, Licciardi PV, Koplin JJ, Martin PE et al. Increasing the
4 350 accuracy of peanut allergy diagnosis by using Ara h 2. *J Allergy Clin Immunol* 2012; 129(4):1056-
5 351 63.
6
7 352 (16) Asarnoj A, Ostblom E, Kull I, Lilja G, Pershagen G, Hedlin G et al. Sensitization to
8 353 inhalant allergens between 4 and 8 years of age is a dynamic process: Results from the BAMSE
9 354 birth cohort. *Clin Exp Allergy* 2008;(9):1507-13.
10
11 355 (17) Asarnoj A, Ostblom E, Ahlstedt S, Hedlin G, Lilja G, van HM et al. Reported
12 356 symptoms to peanut between 4 and 8 years among children sensitized to peanut and birch pollen -
13 357 results from the BAMSE birth cohort. *Allergy* 2010; 65(2):213-9.
14
15 358 (18) Wickman M, Kull I, Pershagen G, Nordvall SL. The BAMSE project: presentation of a
16 359 prospective longitudinal birth cohort study. *Pediatr Allergy Immunol* 2002; 13:Suppl-3.
17
18 360 (19) Strachan D, Sibbald B, Weiland S, Ait-Khaled N, Anabwani G, Anderson HR et al.
19 361 Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the
20 362 International Study of Asthma and Allergies in Childhood (ISAAC). *Pediatr Allergy Immunol* 1997;
21 363 8(4):161-76.
22
23 364 (20) Brough HA, Makinson K, Penagos M, Maleki SJ, Cheng H, Stephens AC et al.
24 365 Distribution of peanut protein in the home environment. *J Allergy Clin Immunol* 2013; 132(3):623-9.
25
26 366 (21) Hornung RW, Reed LD. Estimation of average concentration in the presence of
27 367 nondetectable values. *App Occup Environ Hyg* 1990; 5:46-51.
28
29 368 (22) Baurecht H, Irvine AD, Novak N, Illig T, Buhler B, Ring J et al. Toward a major risk
30 369 factor for atopic eczema: Meta-analysis of filaggrin polymorphism data. *J Allergy Clin Immunol* 2007;
31 370 120(6):1406-12.
32
33 371 (23) Weidinger S, O'Sullivan M, Illig T, Baurecht H, Depner M, Rodriguez E et al. Filaggrin
34 372 mutations, atopic eczema, hay fever, and asthma in children. *J Allergy Clin Immunol* 2008;
35 373 121(5):1203-9.
36
37 374 (24) Garcia-Boyano M, Pedrosa M, Quirce S, Boyano-Martinez T. Household almond and
38 375 peanut consumption is related to the development of sensitization in young children. *J Allergy Clin*
39 376 *Immunol* 2016; 137(4):1248-51.
40
41 377 (25) Brough H.A., Liu.A, Sicherer S., Makinson K., Douiri A., Wood R. et al. Atopic
42 378 dermatitis increases the impact of exposure to peanut antigen in dust on peanut sensitization and
43 379 allergy. *Allergy Supplement*. 2014.
44 380 Ref Type: Abstract
45
46 381 (26) Hill DJ, Hosking CS, Oranje AP, Bauchau V, Naspitz CK, Simons FER et al.
47 382 Confirmation of the association between high levels of immunoglobulin E food sensitization and
48 383 eczema in infancy: An international study. *Clin Exp Allergy* 2008; 38(1):161-8.
49
50 384 (27) Brown SJ, Asai Y, Cordell HJ, Campbell LE, Zhao Y, Liao H et al. Loss-of-function
51 385 variants in the filaggrin gene are a significant risk factor for peanut allergy. *J Allergy Clin Immunol*
52 386 2011; 127(3):661-7.
53
54 387 (28) Du Toit G, Roberts G, Sayre P, Plaut M. Identifying infants at high risk of peanut
55 388 allergy - The LEAP Screening Study. *J Allergy Clin Immunol* 2013; 131(1):135-43.
56
57
58
59
60

389 (29) Brough H.A., Simpson A., Makinson K., Sara B., Douiri A., Belgrave D. et al.
390 Filaggrin null mutations increase the impact of early environmental peanut exposure on peanut
391 sensitization. Allergy 2013; 68(s97):108.

392 (30) Tariq SM, Matthews SM, Hakim EA, Arshad SH. Egg allergy in infancy predicts
393 respiratory allergic disease by 4 years of age. Pediatric Allergy & Immunology 2000; 11(3):162-7.

394 (31) Gaffin JM, Sheehan WJ, Morrill J, Cinar M, Borrás Coughlin IM, Sawicki GS et al.
395 Tree nut allergy, egg allergy, and asthma in children. Clin Pediatr 2011; 50(2):133-9.

396 (32) Nicolaou N, Poorafshar M, Murray C, Simpson A, Winell H, Kerry G et al. Allergy or
397 tolerance in children sensitized to peanut: prevalence and differentiation using component-resolved
398 diagnostics. J Allergy Clin Immunol 2010; 125(1):191-7.

399 (33) Beyer K, Grabenhenrich L, Hartl M, Beder A, Kalb B, Ziegert M et al. Predictive
400 values of component-specific IgE for the outcome of peanut and hazelnut food challenges in
401 children. Allergy 2015; 70(1):90-8.

402 (34) Besharat PM, Bergstrom A, Bottai M, Kull I, Wickman M, Hakansson N et al. Effect of
403 parental migration background on childhood nutrition, physical activity, and body mass index. J
404 Obesity 2014; 2014:406529.

405
406

Table EI: Demographics of whole studied BAMSE population with available dust and *FLG* genotyping (n=1878)

	Number of cases	No. data points	Percentage
Peanut specific IgE ≥ 0.35kU/L at 4 years	103	1572	6.55%
Peanut specific IgE ≥ 0.35kU/L at 8 years	161	1876	8.58%
Ara h 1, 2 or 3 ≥0.35kU/L at 8 years vs. Ara h 1, 2 or 3 <0.35kU/L or peanut sIgE <0.35kU/L (excluding peanut sIgE ≥0.35kU/L with no components)	75	1854	4.05%
Avoiding peanut because of previous adverse reaction	73	1878	3.89%
History of infantile atopic dermatitis	313	1840	17.01%
At least one <i>FLG</i> mutation (R501X, 2282del or R2447x)	134	1878	7.14%
Allergic rhinitis (ISAAC definition) (age 4 years)	215	1828	11.76%
Allergic rhinitis (ISAAC definition) (age 8 years)	288	1865	15.44%
Egg sIgE ≥ 0.35IU/ml at 4 years of age	82	1575	5.21%
Male gender	973	1871	52.00%
Caucasian ethnicity	1677	1842	91.04%
Biological siblings	1695	1870	90.64%
Parental atopy – (asthma/AR/AD)	838	1858	45.10%
Maternal age (mean, SD)	30.9 (SD4.49)	1871	N/A
Peanut protein in maternal bed-dust (µg/g): median [IQR]	4.07 [1.58-11.86]	1878	N/A
Exclusive breast-feeding duration (months): mean (SD)	5.19 (2.43)	1838	N/A
Total breast-feeding duration (months): mean (SD)	8.73 (3.31)	1825	N/A

Table I: Univariate conditional logistic regression incorporating matching for peanut sensitized cases versus non-sensitized controls matched for gender and parental atopy. Peanut sIgE sensitization (≥ 0.35 kU/L) at age 4 years and peanut PAM sensitization (Ara h 1, 2 or 3 ≥ 0.35 kU/L) at age 8 years.

	Peanut sIgE sensitized at age 4 years (n=411)			Peanut PAM sensitized at age 8 years (n=195)		
	OR	95% CI	P value	OR	95% CI	P-value
EPE (μ g/gram ln transformed)	1.23	1.06-1.43	<.01	1.29	1.04-1.61	.02
No. of biological siblings	1.38	0.63-3.03	.42	2.50	0.77-8.16	.13
≥ 1 <i>FLG</i> loss-of-function mutation (excluding non-caucasians)	2.67	1.18-6.04	.02	3.00	0.84-10.75	.09
History of infantile eczema	7.35	4.20-12.83	<.001	6.39	2.95-13.83	<.001
Egg sIgE sensitization: 4 years	18.91	7.50-47.66	<.001	12.85	3.78-43.67	<.001
Allergic rhinitis: 4 years (ISAAC)	3.44	1.90-6.23	<.001	2.53	1.04-6.18	.04
Allergic rhinitis: 8 years (ISAAC)	11.44	5.68-23.07	<.001	12.97	4.54-37.05	<.001
Exclusively breastfed (months)	0.95	0.88-1.03	.22	0.98	0.87-1.11	.77
Breastfed (excl/partial) (months)	0.99	0.93-1.05	.74	1.01	0.93-1.11	.76
Maternal age at baseline (in years)	0.99	0.94-1.04	.65	1.05	0.99-1.12	.12

415

Table II: Multivariate conditional logistic regression incorporating matching for peanut sensitized cases versus non-sensitized controls matched for gender and parental atopy. Peanut sIgE sensitization (≥ 0.35 kU/L) at age 4 years and peanut PAM sensitization (Ara h 1, 2 or 3 ≥ 0.35 kU/L) at age 8 years. Non-caucasians excluded due to inclusion of *FLG* mutations as covariate.

	Peanut sIgE sensitized at age 4 years (excluding non-caucasians) (n=237)			Peanut PAM sensitized at age 8 years (excluding non-caucasians) (n=143)		
	*AIC: 90.78			*AIC: 49.19		
	OR	95% CI	P Value	OR	95% CI	P Value
EPE (μ g/gram ln transformed)	1.41	1.05-1.90	.02	2.11	1.38-3.22	.001
≥ 1 <i>FLG</i> loss-of-function mutation	3.78	0.93-15.36	.06	7.33	1.21-44.21	.03
History of infantile eczema	2.53	0.98-6.51	.05	3.93	1.03-15.00	.05
Egg sIgE sensitization: 4 years	28.00	5.24-149.39	<.001	39.9	1.47-1081.68	.03
Allergic rhinitis: 8 years (ISAAC)	12.57	4.164-37.98	<.001	28.93	3.77-221.61	<.001

*Smaller AIC is better

Table III: Univariate analysis of peanut specific IgE sensitization aged 4 and 8 years using GEE to account for repeated measures within individuals at 4 and 8 years and logistic regression for peanut PAM sensitization at age 8 years in the whole BAMSE cohort (n=1878).

	Univariate GEE for peanut slgE sensitization at 4 and 8 years			Univariate peanut PAM sensitization at age 8 years		
	OR	95% CI	<i>P</i> Value	OR	95% CI	<i>P</i> Value
EPE (µg/gram ln transformed)	0.95	0.86-1.06	.39	1.01	0.86-1.19	.89
Gender	1.14	0.83-1.56	.43	1.41	0.88-2.26	.15
Full older siblings	1.08	0.63-1.85	.77	0.86	0.40-1.81	.68
≥1 <i>FLG</i> loss-of-function mutations (excluding non-caucasians)	1.85	1.08-3.16	.03	1.76	0.82-3.77	.15
History of infantile eczema	6.49	4.66-9.02	.001	7.94	4.91-12.83	<.001
Egg slgE sensitization at 4 years	13.58	8.55-21.58	<.001	11.04	6.13-19.90	<.001
Allergic rhinitis aged 4 years (ISAAC)	2.82	1.92-4.13	<.001	2.16	1.22-3.83	<.01
Allergic rhinitis aged 8 years (ISAAC)	8.05	5.78-11.22	<.001	5.87	3.66-9.42	<.001
Parental atopy (asthma and/or hay-fever)	1.77	1.28-2.44	<.001	1.77	1.10-2.83	.02
Non-caucasian ethnicity	1.58	0.97-2.57	.07	1.09	0.49-2.43	.79
Exclusively breastfed in months	0.98	0.94-1.06	.92	0.97	0.88-1.06	.49
Breastfed (exclusive/partial) in months	0.99	0.94-1.03	.57	0.97	0.91-1.04	.43
Maternal age at baseline (in years)	1.02	0.98-1.05	.44	1.02	0.97-1.07	.53

Table IV: Multivariate analysis of peanut specific IgE sensitization aged 4 and 8 years using generalised estimating equations (GEE) to account for repeated measures within individuals at 4 and 8 years and logistic regression analysis for peanut PAM sensitization at age 8 years in the BAMSE cohort. excluding non-caucasians. Goodness of fit assessed by QIC and AIC.

	Multivariate peanut sIgE sensitization (excluding non-caucasians) (1388) QIC:1094			Multivariate peanut PAM sensitization (excluding non-caucasians) (n=1375) AIC:767		
	OR	95% CI	P Value	OR	95% CI	P Value
EPE (µg/gram ln transformed)	0.98	0.84-1.13	.75	1.08	0.88-1.32	.48
≥1 <i>FLG</i> loss-of-function mutations	2.37	1.22-4.60	.01	1.82	0.72-4.57	.20
History of infantile eczema	3.81	2.44-5.94	<.001	5.51	3.03-10.03	<.001
Egg sIgE sensitization at 4 years	8.12	4.35-15.15	<.001	6.61	3.16-13.80	<.001
Allergic rhinitis aged 8 years (ISAAC)	5.57	3.57-8.71	<.001	3.05	1.65-5.63	<.001

Review

Table V: Univariate analysis of factors associated with peanut PAM sensitization (at age 8 years) versus non peanut PAM sensitization (at age 8 years) in high risk children with preceding egg sensitization (at age 4 years) (n=134).

	Peanut PAM sensitization vs. non-peanut sensitized egg sensitized controls		
	OR	95% CI	P Value
EPE (µg/gram In transformed)	1.33	1.01-1.74	<0.05
Gender	1.90	0.95-3.80	0.07
Full older siblings	0.61	0.17-2.13	0.44
≥1 <i>FLG</i> loss-of-function mutations (excluding non caucasians)	1.09	0.33-3.56	0.89
History of infantile eczema	2.51	1.24-5.08	0.01
Allergic rhinitis aged 4 years (ISAAC)	0.87	0.38-1.96	0.73
Allergic rhinitis aged 8 years (ISAAC)	2.65	1.26-5.56	0.01
Parental atopy (asthma and /or hay-fever)	1.34	0.67-2.65	0.41
Non-caucasian ethnicity	2.55	0.93-6.98	0.07
Exclusively breastfed in months	0.89	0.77-1.04	0.14
Breastfed (exclusive/partial) in months	0.99	0.89-1.09	0.76
Maternal age at baseline (in years)	1.06	0.99-1.14	0.11

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Legend

Figure 1: Mean predictive probability of peanut sensitization in children with primary peanut PAM sensitization (Ara h 1,2 or 3 ≥ 0.35 kU/L) versus children with peanut specific IgE ≥ 0.35 kU/L but with negative results for peanut PAM (Ara h 1,2 or 3 < 0.35 kU/L).

Contributions of each author

HB, IK, EH, MW, GL had substantial contributions to the conception and design of the study. HB, KM, MP and VR made substantial contributions to acquisition of peanut-dust data and analysis. HB and AD performed the statistical analysis of results. IK, EH, CS, AB, EM and MW had substantial contribution to the BAMSE study and obtaining data to perform this study. CS performed the FLG genotyping. All authors contributed to the drafting and revising the manuscript for intellectual content and have approved the version to be published.

Conflict of interests

H. A. Brough has received research support from the National Peanut Board and has received research support, lecture fees, and travel support from Thermo Fisher Scientific. G. Lack and V. Turcanu have received research support from the National Peanut Board. I Kull, K Makinson, E Hallner, C Söderhäll, A Douiri, M Penagos, E Melén, A Bergström and M Wickman declare that they have no relevant conflicts of interest.

Comments for Authors:

This interesting article in which the authors to investigated whether epicutaneous peanut exposure is related to peanut (component) sensitization at year 4 and year 8. This work is important and relevant to explore a possible relationship between the household peanut consumption and the development of peanut allergy especially as it is investigated in an unselected birth cohort. However, I have concerns about the methodology used and therefor about the interpretation and conclusions drawn from the results of this article.

Major points:

- Was the stepwise data analysis (a nested case control analysis followed by whole cohort analysis) chosen for (cost)-efficiency or other reasons? Please explain, because if possible and data are available you should prefer to use the whole cohort analysis to answer your research questions properly.

The reviewer is correct that the stepwise data analysis (a nested case control analysis followed by whole cohort analysis) was chosen for financial and logistical reasons. Both the peanut levels in dust and filaggrin analysis had not yet been performed thus required the finances and manpower to run these analyses. We wanted to see if there was a difference in peanut levels in dust between peanut sensitised cases and high risk controls (matched for parental atopy) (n=411) before proceeding with the whole cohort (n=1878). We have stated 'The analysis was done in two steps for financial and logistical reasons' into the last paragraph of the introduction (line (track changes manuscript) 130) to highlight this.

- I think the OR's throughout the article should be interpreted with care here as an association was found and no causation. It would be better to speak about an increased probability of developing sensitization to peanut with each unit increase of EPE instead of a x% risk for peanut sensitization.

We agree with the reviewer that the OR represent association and not causation. We have therefore amended the text as suggested throughout the manuscript.

- Several confounders should be addressed that can influence the association found between EPE and peanut sensitization: the severity of the child's eczema, the use of emollients and / or topical steroids, parental atopy (including AD), parental

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

peanut / food allergy, other food allergies in the child (besides egg allergy), oral exposure to peanut).

Thank-you for suggesting these potential confounders. We will discuss each in turn including their association with peanut sensitization at age 8 years:

- 1) In BAMSE the severity of the child's eczema was assessed by the extent of localisation reported by the parents in the questionnaire at 1 year of age. The extent of localisation of eczema was up to 10 areas (face, scalp, arms/legs, armpits, flexures, wrists/ankles, neck, chest/belly or back, front body inside nappy, buttocks). The extent of localisation of infantile eczema was associated with peanut sensitization on univariate analysis (Table III and V) but was no longer significantly associated on multivariate analysis. There was no significant interaction between EPE and extent of eczema localisation on peanut sensitization.*
- 2) Use of topical steroids was reported by parents within the last year (from age 1-2 years) at the 2 year questionnaire. Use of topical steroids was associated with peanut sensitization on univariate analysis (Table III and V) but was no longer significantly associated on multivariate analysis. There was no significant interaction between EPE and use of topical steroids on peanut sensitization.*
- 3) We included both definitions of parental atopy (with and without eczema) in the demographics Table E1, methods section and results section for the whole cohort analysis. On univariate logistic regression analysis (Table III), the association between parental atopy (excluding eczema) and primary peanut sensitization at age 8 years was significant (OR 1.77 (95% CI: 1.1-2.83) $p=0.02$), whereas the association between parental atopy (including eczema) was not significant (OR 1.50 (95% CI: 0.95-2.39), $p=0.09$). We postulate that adult eczema may be non-atopic and therefore is not related to an increased risk of atopy in the child. To demonstrate thus we evaluated the rate of eczema within the first year of life in children with parental atopy that did or did not include eczema. We found that 24% (143/595) of children with parental atopy excluding eczema had infantile eczema whereas only 22.5% (185/823) of children with parental atopy including eczema had infantile eczema. We therefore used the definition of parental atopy excluding eczema*

throughout the rest of the manuscript. We have explained this in the methods section (line (track changes manuscript) 160-165):

'This definition of parental atopy was selected rather than the same definition with inclusion of a doctor's diagnosis of eczema (excluding contact dermatitis); this was because the children of parents with atopy including eczema were less atopic (lower infantile eczema) and parental atopy including eczema was not associated with the outcome of interest (primary peanut sensitization at 8 years of age); this is probably because adult eczema is often non-atopic.'

- 4) *The BAMSE study does not have information on parental peanut or food allergy or maternal peanut consumption during pregnancy or breastfeeding.*
- 5) *The BAMSE study does not have information on oral consumption of peanut in the child in the first year of life.*
- 6) *The association between other food allergies in the child (besides egg allergy) and primary peanut sensitization at age 8 years was assessed using parental questionnaires at the 8 year visit where the parents were asked: 'Is your child allergic to any foodstuff?' An adverse reaction included itching in the mouth, nose/eye problems, trouble breathing, vomiting or diarrhoea, eczema or nettle rash. Parents were then asked the same questions about specific foods: milk, egg, fish, shell-fish, wheat, soy, apple, peach, kiwi, avocado, raw carrot, banana, nuts/almond (except peanut). Results are shown in Table III, IV and V in the manuscript. Although the majority of the adverse reactions to foods at age 8 were associated with peanut sensitization, on multivariate analysis only tree nut and soya adverse reactions were significantly associated.*

- To answer the question whether FLG loss-of-function mutations, infantile eczema and preceding egg sensitization have modifying effects on the association between EPE and peanut sensitization selective samples based on the outcome were drawn from the cohort (peanut PAM sensitized versus egg sensitized children). However, to conclude whether those proposed factors are effect modifiers, the association between EPE and the outcome should be investigated in both strata (with and without the possible effect modifier). For example it should be investigated if there is a difference in the association between EPE and peanut sensitization in children with eczema compared to children without eczema.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The reason we analysed the level of EPE in peanut sensitized versus egg-sensitized, peanut-tolerant individuals was because we wanted to mimic the analysis by Fox et al (J Allergy Clin Immunol 2009;123:417-23) who compared level of household peanut consumption in peanut allergic cases versus egg allergic non-peanut allergic infants. In the study by Fox et al. it was shown that household consumption of peanut (as a marker of environmental exposure to peanut) was associated with peanut allergy especially when compared against egg allergic, non-peanut allergic controls.

We assessed whether there was an interaction between EPE and peanut sensitization in children with or without infantile eczema, egg sensitization, FLG mutations and parental atopy and there were no significant associations.

Abstract

- Line (track changes manuscript) 35 Please explain what kind of statistical analysis are performed (dependent / independent variables and which kind of modelling) in which subgroup.

We have provided an overview of the dependent (outcome) variable and main independent variables (EPE) for the case control, cohort and subgroup analysis and have stated which statistical analysis was used (line (track changes manuscript) 36-43):

'Initial nested case control analysis was performed comparing peanut sensitized cases against high-risk controls (matched for parental atopy) (n=411) using a conditional regression analysis. This was followed by whole cohort analysis (n=1878) comparing EPE against peanut sIgE sensitization at ages 4 and 8 years using Generalized Estimating Equations and against primary peanut sensitization at age 8 years using a logistic regression model. Finally, a subgroup analysis was performed comparing the impact of EPE in peanut sensitized versus egg-sensitized peanut tolerant individuals using logistic regression analysis. Levels of EPE were compared between groups using the Mann-Whitney U test.'

- Line (track changes manuscript) 37 I find this sentence difficult to interpret. Do you mean that a higher level of EPE (in µg/gram? Or the highest quartile compared to the lower quartiles?) around birth was significantly associated with the presence of peanut sensitization (>0.35kU/L) at year 4?

We mean that a higher level of EPE around birth (in $\mu\text{g}/\text{gram}$) is associated with the presence of peanut sensitization at age 4 years (we did not compare quartiles). We have amended the sentence to make this clearer as follows (line (track changes manuscript) 45-48):

'In the nested case control analysis, a higher level of EPE around birth was associated with the presence of peanut specific IgE sensitization at age 4 years (OR=1.41, 95% CI:1.05-1.90), and primary peanut sensitization at age 8 years (OR=2.11, 95% CI:1.38-3.22) compared against high-risk controls.

Introduction

- Line (track changes manuscript) 110 What do you mean with a high risk population, did you select children with certain risk factors for peanut sensitization for this analysis?

We determined these children to be at higher risk of developing peanut allergy as the controls were matched to the higher level of parental atopy that was present in the primary peanut sensitised cases than in the population overall (46.7% vs. 32.6%). This clarification has been added to the methods (line (track changes manuscript) 207-210).

'Given that these controls were matched for the higher levels of parental atopy in the primary peanut sensitized cases these controls were deemed to be high-risk as the primary peanut sensitized cases had higher levels of parental atopy than the population overall (46.7% vs. 32.6%).'

Methods

- Did you consider to take a lower limit of sIgE sensitization (especially to peanut components) as clinically relevant, e.g. $> 0.1 \text{ kU/l}$?

The results for peanut specific IgE were reported with a cut-off of 0.35 kU/l ; however, Ara h 1,2 and 3 were reported with a lower cut-off of 0.1 kU/l . There were 11 data points that became positive when we redid the analysis using a cut-off of 0.1 kU/L instead of 0.35 kU/l . We redid the analysis using primary peanut sensitization (Ara h 1,2 and/or 3) with a cut-off of 0.1 kU/l and there was no association between EPE and primary peanut sensitization at age 8 years and the other covariate associations did

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

not significantly change therefore we have kept the analysis using a cut-off for Ara h 1,2 and/or 3 of 0.35kU/l.

- Line (track changes manuscript) 126 Regarding the non-available PAM analysis data: in how many cases occurred missing data?

In line (track changes manuscript) 126 we stated 'children with positive peanut specific IgE at 8 years of age but with no available peanut protein component allergen analysis were excluded from this analysis.' There were 24 children with missing data for this analysis because no serum was available to perform this. This has now been included in the manuscript of the text (line (track changes manuscript) 151-153).

'Twenty-four (1.3%) children with positive peanut specific IgE at 8 years of age but with no available serum for peanut protein component allergen analysis were excluded from this analysis.'

- Was there a selection of children in which PAM analysis was performed and can this have influenced your results?

All children sensitized to peanut at age 8 years, irrespective of sensitization to birch had analysis of Ara h 1,2,3,8 and 9 where enough sample was available. In addition, those children who were peanut sensitized at age 4 years but lost their sensitization at age 8 were also analysed for these component allergens. All children with negative peanut sIgE at age 8 years were assumed to have negative component allergens to peanut. We believe this selection is broad enough so as not to have biased our results. This information has been added to the manuscript (line (track changes manuscript) 142-148).

'Peanut protein component allergens Ara h 1,2,3,8 and 9 were assessed at 8 years (ImmunoCAP system, ThermoFisher, Sweden) in all children sensitized to peanut at age 8 years, irrespective of sensitization to birch. In addition, those children who were peanut sensitized at age 4 years but lost their sensitization at age 8 were also analyzed for these allergens. All other children with negative peanut sIgE at age 8 years were assumed to have negative component allergens to peanut.'

- 1
2
3 - Line (track changes manuscript) 128 Why was eczema not taken in to account in
4 the parental atopy definition?
5
6

7
8 *We have included both definitions of parental atopy (with and without a history of*
9 *eczema) in the demographics Table E1, methods section and results section for the*
10 *whole cohort analysis. Please see response to previous question by the same*
11 *reviewer.*
12
13

- 14
15 - How was the presence of a furred pets- and / or pollen allergy determined?
16
17

18 *'Doctor diagnosed furred pets- and / or pollen allergy' was self-reported by the*
19 *mother and/or father for the parental atopy definition in the BAMSE questionnaire.*
20
21

- 22
23 - Was the GEE modelling only used to select possible predictors of the presence
24 of peanut sensitization? And why did you choose for GEE with repeated measures
25 and not for one logistic regression model with any sensitization to peanut at age 4
26 and/or age 8 as outcome measure?
27
28

29
30 *GEE modelling was used to select possible predictors of the presence of peanut sIgE*
31 *sensitization at age 4 and 8 years using first a univariate then multivariate analysis.*
32 *In the multivariate analysis variables were only included if were significantly*
33 *associated with peanut sensitization ($p \leq 0.05$) and if their inclusion also improved the*
34 *quality of fit of the multivariate model using Quasi Likelihood Independence model*
35 *criterion (QIC) or Akaike information criterion (AIC).*
36
37
38
39

40
41 *We used GEE with repeated measures rather than one logistic regression model with*
42 *any sensitization at peanut at age 4 or age 8 as the outcome measure to account for*
43 *missing data. GEE has built in imputation for missing results using the maximum*
44 *likelihood analysis. This accounts for bias that could be introduced as if the child is*
45 *peanut sensitized at age 4 and data is missing at age 8 they would be presumed to*
46 *be peanut sensitized but if they were not peanut sensitized at age 4 and data was*
47 *missing at age 8 years they would be excluded from the analysis.*
48
49
50
51

52 53 54 55 Results

- 56 - Table I it would be interesting to split this table according to outcome
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 is split according to the outcome at 4 and 8 years. Please advise if you would like us to change the structure of the Table.

- Table II why was allergic rhinitis at year 8 entered in the model instead of year 4 (as the outcome was assessed at year 4)?

Allergic rhinitis at age 8 years was selected as it improved the fit of the conditional logistic regression model (AIC) better than allergic rhinitis at age 4 years. As described in the statistical methods 'In the multivariate analysis variables were only included if were significantly associated with peanut sensitization ($p \leq 0.05$) on univariate analysis and if their inclusion also improved the quality of fit of the multivariate model using Quasi Likelihood Independence model criterion (QIC) or Akaike information criterion (AIC). This clarification has been added as a footnote to Table II.

- Table E1 Almost 4 % of patients is already avoiding peanut due to a previous adverse reaction. At which point in time was this question asked?

This question was asked at age 8 years; however, we realised that a slightly different question was more likely to indicate relevant peanut allergy. Parents were asked 'Is your child allergic to any foodstuff?' which encompassed nose and eye symptoms, itch, breathing problems, diarrhoea, eczema, rash, ' then were asked about specific foods: 'Any reaction to peanut?'. The question about peanut avoidance did not encompass any allergic symptoms.

Also 'Any reaction to peanut' and was much more highly associated with primary peanut sensitization (OR 157.6 95% CI: 81-305), $p < 0.0001$) than 'avoiding peanut because of adverse reaction' (OR 51.2 95% CI: 29-91, $p < 0.0001$), therefore we used the definition 'Any reaction to peanut' and also used this definition for other food allergies.

Do you have more information on the presence of clinical relevant peanut allergy?

Unfortunately no diagnostic oral food challenges were performed as part of the BAMSE study as the study was not designed to assess peanut allergy.

- 1
2
3 - Table E1: parental atopy AD seems included in contrast to the definition
4 described in the method section of the article.
5
6

7 *We thank the reviewer for pointing out this mistake; this was not meant to state 'AD'.*
8 *However, we now include results for parental atopy which include and exclude*
9 *eczema methods and results and Table III.*
10
11

- 12
13 - Line (track changes manuscript) 219 Did you also investigate whether there was
14 an interaction between EPE and parental atopy and peanut sensitization?
15
16

17
18 *In line (track changes manuscript) 267-269 we stated that in the nested cases*
19 *analysis 'There was no significant interaction between EPE and either infantile*
20 *eczema, egg sensitization or FLG loss-of-function mutations on primary peanut*
21 *sensitization (data not shown).'*
22
23

24
25 *We were not able to assess an interaction between EPE and parental atopy with*
26 *peanut sensitization as the case control analysis was set up by matched for parental*
27 *atopy.*
28
29

30 Discussion

- 31
32 - In the light of my questions and comments regarding possible confounders and
33 effect modifiers between the association of EPE and peanut sensitization, it would be
34 necessary to comment on this in the discussion section of the manuscript.
35
36

37
38 *We have included a discussion of the additional variables included in the analysis*
39 *(eczema severity and allergic reactions to a specific food by age 8 years) in the*
40 *discussion (lines (track manuscript) 353-359 and 372-375):*
41
42

43
44 *'Measures of eczema severity (extent of localisation, topical steroid use and*
45 *persistent eczema) were associated with primary peanut sensitization on univariate*
46 *analysis but were no longer associated on multivariate analysis. Eczema severity has*
47 *previous been shown to be an independent risk factor for food sensitization in the*
48 *EAT (Enquiring About Tolerance) study.²⁸ The EAT study used the SCORAD eczema*
49 *severity scoring system; however, this could not be performed in the BAMSE study*
50 *as the evaluations at 1,2,4 and 8 years were based on parental questionnaires. Tree*
51 *nut and/or soya allergy by age 8 was also associated with primary peanut*
52 *sensitization at age 8 years; co-existent peanut and tree-nut allergy has been shown*
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

in numerous studies,^{32, 33} whereas co-existent soya and peanut allergy is reportedly low.³⁴

We have also included a section in the discussion outlining the variables that we could not include which may be possible confounders (line (track changes manuscript) 380-386):

‘Certain potential confounders were not available such as parental peanut allergy or other parental food allergies, maternal peanut consumption during pregnancy and breast-feeding and infant peanut consumption. Therefore we are unable to assess whether infant peanut consumption could have protected the children against environmental exposure to peanut as has been shown in previous studies;^{12, 32} however, when BAMSE was recruiting participants in 1996 the number of infants eating peanut was very low.’

- How does the amount of EPE in this birth cohort study correspond to other studies?

The median level of peanut protein in maternal bed-dust dust in the BAMSE cohort 4.07µg/gram [IQR 1.58, 11.86] was similar to that found in another the UK study by our group (median 4.19 IQR 0.54-24.89) (Brough et al 2013 JACI; 132(3):623-9).

The level of peanut in dust was higher in a US study (Brough et al. JACI 2015; 135(1):164-70) that measured peanut from the living room floor (median 39.1ug/g IQR 0.4-1.33). It would however be expected that peanut levels would be higher in America due to higher levels of peanut consumption. This information has been added to the discussion of the manuscript (line (track changes manuscript) 339-344).

- How do you explain the difference between the association of EPE with extract versus component sensitization?

We believe the difference between the association of EPE with extract versus component peanut sensitization supports the hypothesis that EPE increases the probability of developing clinically relevant peanut sensitization, and therefore that these children are more likely to develop peanut allergy.

In previous work, Brough et al. (2013 JACI) showed that peanut allergens in dust were able to activate basophils of peanut allergic individuals in an allergen specific manner. We therefore hypothesise that peanut levels in dust are also able to interact with dendritic cells and T cells in the development of clinically relevant peanut allergic sensitization.

- Line (track changes manuscript) 269 How does your data support this conclusion?

In line (track changes manuscript) 268-270 we stated: 'we did show on subgroup analysis that early EPE has more impact in children with certain risk factors for the development of peanut sensitization (such as parental atopy or egg sensitization) than children without these risk factors'. Our data support this conclusion because in our nested cases analysis, the association between EPE and peanut sensitization was stronger when comparing peanut sensitized cases versus high risk controls (matched for parental atopy). In the whole cohort analysis the association between EPE and peanut sensitization was stronger when comparing peanut sensitized children versus high risk controls (defined by egg sensitization).

We have amended the sentence in the manuscript to better clarify how our data supports this conclusion (line (track changes manuscript) 332-335): 'we did show on subgroup analysis that early EPE has more impact on the probability of developing peanut sensitization when compared against high risk children (defined by parental atopy in the nested cases analysis and egg sensitization in the whole cohort analysis) than in children without these risk factors'. However, we also state in the discussion that 'findings on case control analysis could not be replicated on whole cohort analysis, therefore these findings need to be confirmed in other population based cohorts.'

Minor points

- Throughout the article the abbreviation "protein allergen molecules (PAM)" is used while this is no common terminology for component resolved diagnostics or sIgE to protein components.
- Line (track changes manuscript) 100 "... (PAM) analysis of sIgE to the seed storage proteins...
- Line (track changes manuscript) 122 "... peanut PAM sensitized if sIgE to..."

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Thank-you for raising this point. We have removed the term protein allergen molecule and PAM and have replaced this by stating sIgE to peanut protein allergen components or where we refer to Ara h 1,2 or 3 >0.35kU/l we state 'primary peanut sensitization'.

- Table E1: the percentage is now confusing why not present a column with missing data separately?

We have clarified that the percentage is the ratio of cases compared to the number of available data points. If the reviewer wishes we can also include a separate table with missing data as E2.

For Peer Review

Reviewer: 2

Comments for Authors:

The paper explores an interesting concept- that early transcutaneous sensitization to peanut allergen is a risk factor for the development of subsequent peanut allergy. I found the paper hard to read with a number of grammatical mistakes and some paragraphs were not very clear. Importantly this includes the last two paragraphs of the Abstract: this is where the average reader makes the decision whether they will read on or move on.

Thank-you for highlighting this. We have made several amendments to the abstract following the comments from reviewers and we hope that this now reads more clearly. In particular we have simplified the conclusion so that it now reads as follows (line (track changes manuscript) 59-63): 'Higher levels of environmental exposure to peanut in the first few months of life appear to increase the probability of developing school age peanut sensitization in atopic children (based on egg sensitization and parental atopy).'

Much reliance is made that the filaggrin loss of function mutations chosen represent the majority of those found in this population but their prevalence appears very low- are other mutations perhaps present which means groups have been mis-classified?

The prevalence of FLG loss-of-function mutations is low as this is an unselected population based birth cohort rather than a high-risk eczema cohort. In European populations the two most prevalent mutations in the FLG gene are 2282del4 and the R501X; this has been widely replicated in many studies. Three FLG mutations analysed (2282del4, R501X and R2447X) had frequencies of 4%, 2% and 1% respectively in the BAMSE study which are similar to the frequencies found in a German cross-sectional material (Weidinger et al JACI Vol 121, No 5, 1203-1209, 2008). The mutation next in frequency (0.2%) is S3247X. It is reasonable to assume that the frequency for this mutation would be at a similar level in the German and Swedish cohorts. S3247X carriers in the BAMSE cohort would therefore have amounted to approximately 4 individuals. Therefore, we do not think that the additional information from these few individuals would change any of the conclusions in our study.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

It would have been valuable to have measured transepidermal water loss in all infants or particularly the high atopy group.

We agree with the reviewer that measurement of transepidermal water loss during infancy would have been a valuable measure of skin barrier function; however, the BAMSE cohort children were recruited in 1996 and at this time the body of evidence linking TEWL to eczema was not yet available.

The study suffers from its design- the reviewer suspects the original hypothesis behind BAMSE did not include measurement of peanut allergen nor the early development of eczema.

The reviewer is correct in stating that the original study design for BAMSE did not include measurement of peanut allergen as peanut allergy was very rare in Sweden in 1996. The early development of eczema was; however, one of the original analyses for the BAMSE study.

It would surely have been preferable to measure peanut allergen in the infant's cot where they spend most of their early life rather than their mother's bed?

Unfortunately dust was not sampled from the infant's cot in the BAMSE study. The rationale for this was that most of the infants recruited to the study were first-borns thus the mattress would have been new. We have, however, shown in a previous publication that there is a high correlation between levels of peanut protein in the bed of the mother and infant-cot (correlation coefficient 0.844 (95% CI: 0.708-0.919), $p<0.001$) during the first year of life. (Brough et al. Distribution of peanut protein in the home environment. J Allergy Clin Immunol 2013;132:623-9).

Definition of eczema based on questionnaire is prone to major errors as has been seen in other epidemiological studies- to reach firm conclusions infants must be regularly examined prospectively.

The eczema questionnaires used at age 1 and 2 years in the BAMSE study were previously validated in the publication by Bohme M et al. (Atopic Dermatitis and Concomitant Disease Patterns in children up to two year of age. 2002;82:98-103).

Fifty consecutive children aged 0-4 years of age were seen in clinic and their parents were asked to fill in this questionnaire before meeting the doctor. The questionnaire contained, among other questions, the questions diagnostic for eczema from the main study questionnaires. The children were then examined by a Dermatologist to determine whether they had eczema according to the criteria from Hanifin JM and Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980; Suppl 92:44-47. The sensitivity of the questionnaire assessment compared with the clinical diagnosis by the dermatologist was 92% and the specificity was 100%. This information has been included in the manuscript (line 171-172) and the reference from Bohme et al has also been included (ref 20).

There is as a result little information of eczema SEVERITY in infancy- which must surely be relevant to degree of sensitization if this hypothesis is correct (peanut sensitization occurs first through the skin).

Eczema severity (defined by extent of localisation of eczema, use of topical steroids and persistent eczema at age 8 years) was positively associated with peanut sensitization on univariate analysis, but was no longer significant on multivariate analysis. This is in contrast to other studies that have shown that eczema severity is an independent risk factor for sensitization; however these studies used SCORAD assessments which were not available in BAMSE.

We are not told of maternal allergic status- could it be allergen levels were lower in some homes because of maternal peanut allergy? Do we know of maternal peanut intake in pregnancy and perhaps more importantly whilst breast-feeding [I understand the majority of Swedish mothers choose to breast feed-] did those with atopic personal or infant history do so for longer?

The BAMSE cohort does not unfortunately have information on parental peanut allergy, parental food allergy or maternal peanut consumption during pregnancy or breastfeeding as it was not originally designed to assess peanut allergic outcomes. There is evidence that mothers breastfed marginally longer in BAMSE if there was one atopic parent vs no atopy (exclusive breastfeeding 79.3% if no parental atopy vs 80.8% if one parent atopic); if both parents were atopic this increased to 85.8% (Kull et al JACI 2004; 114:755-60 (Table 1)). Duration of breastfeeding (both exclusive and partial) has been included as a covariate in the analysis (Table I and III).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

It is hardly surprising infants with eczema have a higher rate of sensitization- this has been repeatedly demonstrated but it has also been demonstrated such sensitization commonly does NOT translate into clinical allergy, something the authors have not sought to demonstrate. It has recently been demonstrated in an ingenious paper (Fukuie T et al (J Dermatol. 2016 Nov;43(11):1283-1292) that measures of sensitization improve as better eczema control is achieved. As the authors of this present study are aware, sensitization does NOT translate into allergy. The authors rely on high levels of specific IgE to components of peanut and argue this reflects a higher likelihood these children are also peanut allergic but a very recent paper has cast serious doubt on the reliability of levels of component-based [protein allergen molecules] specific IgE to predict severe allergy[van Veen et al. BMC Pediatrics (2016) 16:74].

We agree that the presence of IgE directed against peanut protein component allergens does not always translate into allergy; however, the premise of this study was to assess whether environmental peanut exposure is associated with peanut sensitization as the first step towards allergy. We would have liked to assess whether EPE was associated with OFC proven peanut allergy; however, this information was not available in BAMSE as the study was not designed to assess peanut allergic outcomes.

The study by van Veen et al. (BMC Pediatrics; 2016: 16:74) assesses the diagnostic performance of peanut SPT, peanut sIgE to whole extract and peanut sIgE to component allergens (Ara h 1,2 and 3) against oral food challenges to peanut. They found that peanut SPT and peanut sIgE against component allergens were significantly associated with a positive outcome on peanut oral food challenge ($p<0.0001$); however, they were not associated with the severity of reaction or eliciting dose on food challenge.

In this manuscript we did not assume that primary peanut sensitization (Ara h 1,2 or 3 $>0.35kU/l$) was linked to severe peanut allergy; only that it was more likely to predict clinical peanut allergy (regardless of the level of severity).

I am surprised the authors report allergic rhinitis at 8 years in these groups (which appears at least at first sight to have little to do with peanut sensitization or allergy but may have minor interest in understanding false-positive specific IgE to Ara-8) but

do not report how many children still suffer from eczema- a surrogate marker of their early eczema severity.

We did indeed include allergic rhinitis at 8 years as a marker for false positive IgE directed against Ara h 8. We have now included this information as a footnote of Table 1. Eczema at age 8 years (OR 2.85, 95% CI: 1.69-4.81, $p < 0.0001$) was associated with peanut sensitization at age 8 years on univariate analysis but was no longer associated on multivariate analysis.

The authors should discuss why cutaneous peanut exposure in British and Swedish children with early onset eczema is apparently associated with later peanut sensitization (and purportedly peanut allergy) whereas high levels of exposure in the same circumstances in Israel (where early infantile eczema is also very common and where peanut consumption is actually higher than either of those European countries) does not.

In Israel, infants are weaned onto a peanut containing food from 4 months of age which we believe is the reason why children in Israel do not have high levels of peanut allergy despite high household peanut consumption. This observation was published by (Du Toit G JACI 2010) and was the basis of the intervention for the LEAP study. The protective effect of infant peanut consumption against environmental peanut exposure was also shown in the paper by Fox et al. (J Allergy Clin Immunol 2009;123:417-23) where household peanut consumption during infancy increased the risk of developing peanut allergy, but not in children already consuming peanut during the first year of life. The Dual Allergen Exposure Hypothesis (Lack G JACI 2010) describes this balance of exposures during the first year of life where depending on whether the exposure to peanut is through the skin or gut, the immune system is then primed to develop allergy versus tolerance respectively.

We unfortunately do not have information on peanut consumption during infancy in the BAMSE study, thus we are unable to show the protective effect of oral consumption on preventing the development of peanut allergy. However peanut consumption in 1996 in Sweden was low. We have added the following text into the discussion (line (track changes manuscript) 380-386):

'Certain potential confounders were not available as the BAMSE study was not originally designed to evaluate risk factors for peanut allergy, such as parental

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

*peanut or other food allergy, maternal peanut consumption during pregnancy and breast-feeding and infant peanut consumption. Therefore we are unable to assess whether infant peanut consumption could have protected the children against peanut sensitization as has been shown in previous studies (Fox et al. *J Allergy Clin Immunol* 2009;123:417-23, Du Toit G et al. *J Allergy Clin Immunol*. 2008 Nov;122(5):984-91); however, when BAMSE was recruiting participants in 1996 the number of infants eating peanut was very low.'*

It is also disappointing studies where at risk infants are prospectively treated with emollient (to reduce skin exposure to allergens) have shown whilst eczema severity is reduced, allergic sensitization is not.

*We agree that the study by Horimukai K et al. *JACI* 2014 did not show a reduction in sensitization to egg despite a 32% reduction in eczema; however, the IgE measurements for egg used in this study were not standard immunoCAPS therefore we are unsure as to validity of these measures. In addition, this was a small study thus with larger numbers an effect may be seen given that there was a higher egg sensitization rate in those children who developed eczema versus in children who did not develop eczema (odds ratio, 2.86; 95% CI, 1.22-6.73). We await the results of the Barrier Enhancement and Eczema Prevention (BEEP) study which will be assessing peanut sensitization after emollient application during infancy.*

1 Environmental peanut exposure increases the risk of peanut sensitization in high
2 risk children

3 Helen A. Brough FRCPCH PhD*,^{1,2} Inger Kull PhD*,^{3,4,5} Kerry Richards MSc,¹ Eva Hallner,³
4 Cilla Söderhäll PhD,^{6,7,8} Abdel Douiri PhD,⁹ Martin Penagos MD MSc,¹ Erik Melén,^{3,5}
5 Anna Bergström,^{3,7} Victor Turcanu PhD,¹ Magnus Wickman MD PhD**,³ Gideon Lack MD
6 FRCPCH**,^{1,2}

7 ¹ Paediatric Allergy, Department of Asthma, Allergy and Respiratory Science, Division of Asthma
8 Allergy and Lung Biology, MRC & Asthma UK Centre for the Allergic Mechanisms of Asthma, King's
9 College London, Guys' Hospital, London, SE1 9RT, UK

10 ² Children's Allergy Service, Guy's and St. Thomas's NHS Foundation Trust, Westminster Bridge
11 Rd, London SE1 7EH.

12 ³ Institute of Environmental Medicine, Karolinska Institutet and Centre for Occupational and
13 Environmental Medicine, Stockholm County Council, Stockholm, Sweden

14 ⁴ Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm,
15 Sweden

16 ⁵ Sachs' Children's Hospital, Södersjukhuset, Stockholm, Sweden

17 ⁶ Department of Biosciences and Nutrition, Karolinska Institutet, 141 83 Stockholm, Sweden

18 ⁷ Centre of Allergy Research, Karolinska Institutet, Stockholm, Sweden

19 ⁸ Department of Women's and Children's Health, Karolinska Institutet, 171 77 Stockholm, Sweden

20 ⁹ Division of Health & Social Care Research, King's College London, Addison House, Guy's
21 Campus, London SE1 1UL, UK

22 * These authors contributed equally to the manuscript and are joint first authors.

23 **These authors contributed equally to the manuscript and are joint senior authors.

24

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

25 **Word count:** 3528

26 **Short Title:** Environmental peanut exposure and peanut sensitization in BAMSE

For Peer Review

Abstract

Background: High household peanut consumption is associated with the development of peanut allergy, especially when peanut allergic cases are compared against atopic controls; thus environmental peanut exposure (EPE) may be a risk factor for peanut sensitization and allergy. In this study we explored the relationship between EPE and school-age peanut sensitization in a population based cohort.

Methods: Maternal bed-dust was collected postnatally and EPE was quantified using a polyclonal peanut ELISA. Peanut sensitization was assessed by specific IgE to peanut extract and sIgE to peanut protein component allergens Ara h 1, 2 or 3 ≥ 0.35 kU/L (primary peanut sensitization). Initial nested case control analysis was performed comparing peanut sensitized cases against high-risk controls (matched for parental atopy) (n=411) using a conditional regression analysis. This was followed by whole cohort analysis (n=1878) comparing EPE against peanut sIgE sensitization at ages 4 and 8 years using Generalized Estimating Equations and against primary peanut sensitization at age 8 years using a logistic regression model. Finally, a subgroup analysis was performed comparing the impact of EPE in peanut sensitized versus egg-sensitized, peanut tolerant individuals using logistic regression analysis. Levels of EPE were compared between groups using the Mann-Whitney U test.

Results: In the nested case control analysis, a higher level of EPE around birth was associated with peanut specific IgE sensitization at age 4 years (OR=1.41, 95% CI:1.05-1.90), and primary peanut sensitization at age 8 years (OR=2.11, 95% CI:1.38-3.22) compared against high-risk controls. When the whole BAMSE cohort was assessed, EPE was no longer associated with peanut sensitization; however, on subgroup analysis EPE was associated with primary peanut sensitization when compared against egg-sensitized peanut-tolerant controls with an adjusted odds ratio of 1.44 per unit EPE (95% CI:1.06-1.94). There was no significant interaction between EPE and *FLG* loss-of-function mutations, egg sensitization at age 4 years, infantile eczema or parental atopy on peanut sensitization.

53

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusions: Higher levels of environmental exposure to peanut in the first few months of life appear to increase the probability of developing school age peanut sensitization in atopic children (based on egg sensitization and parental atopy).

Abstract word count: 343

Key words: BAMSE, egg sensitization, environmental peanut exposure, *FLG* mutation, infantile eczema peanut sensitization

For Peer Review

61 Funding

62 The research was funded/supported by Action Medical Research (S/P/4529) and by the National
63 Institute for Health Research (NIHR) Clinical Research Facility at Guy's & St Thomas' NHS
64 Foundation Trust and NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS
65 Foundation Trust and King's College London. The views expressed are those of the author(s) and
66 not necessarily those of the NHS, the NIHR or the Department of Health. The BAMSE study was
67 funded by the Swedish Research Council, the Stockholm County Council, the Swedish Research
68 Council for Health, Working life, and Welfare the Swedish Asthma and Allergy Foundation, the
69 Swedish Heart and Lung Foundation, and the Gillberg'ska Foundation.

70 Abbreviations

71 AIC: Akaike information criterion
72 Ara h: *Arachis hypogaea*
73 BAMSE: Children/'Barn' Allergy Milieu Stockholm Epidemiological project
74 CI: confidence intervals
75 EPE: environmental peanut exposure
76 *FLG*: gene encoding the protein filaggrin
77 GEE: Generalized Estimating Equations
78 ISAAC: International Study of Asthma and Allergies in Childhood
79 IQR: Interquartile range
80 QIC: Quasi Likelihood Independence models criterion

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Peanut allergy has increased,^{1, 2} is a leading cause of anaphylaxis in food allergy³ and has a significant impact on quality of life for the child and their family.^{4, 5} Most children react on first known oral exposure to peanut; thus sensitization must be occurring earlier.^{6, 7} Understanding the way children become sensitized to peanut is therefore imperative in order to prevent this condition. Observational⁸ and animal work^{9, 10} suggests that epicutaneous peanut exposure and early onset severe eczema may play an important role in peanut sensitization. Epicutaneous exposure may be the route that peanut levels in dust sensitize a child in early life, particularly if the skin barrier is broken through eczema or specific genetic mutations associated with skin barrier dysfunction (e.g. filaggrin (*FLG*) mutations or eczema). We have recently shown in the Manchester Asthma and Allergy Study (MAAS) and Consortium of Food Allergy Research (CoFAR) cohort that *FLG* loss-of-function mutations and eczema severity respectively can increase the impact of early EPE on peanut sensitization and allergy.^{11, 12}

A dose response relationship has also been demonstrated between household peanut consumption (used as an indirect marker for environmental peanut exposure: EPE) and the risk of developing peanut allergy in young children.¹³ Fox et al. compared household peanut consumption in peanut allergic individuals against children who were at high risk of developing peanut allergy (due to the presence of egg allergy) but had not developed peanut allergy. Household peanut consumption was ten times higher in households with infants with peanut allergy versus children with egg allergy without peanut allergy but was only 3 times higher in non atopic controls, highlighting that household peanut consumption was more likely to be associated with peanut allergy in high risk children.¹³ Household peanut consumption and peanut sensitization has also been associated in other studies.¹⁴ Peanut antigen in the infant's bed-dust and play-area-dust is highly positively correlated with household peanut consumption and stimulates basophils from peanut allergic children, thus has the potential to also sensitize individuals.¹⁵

1
2
3 108 Peanut sensitization (specific IgE $\geq$ 0.35kU/L) is present in up to 10% of children and protein allergen
4
5 109 molecule analysis of the seed storage proteins in peanut (Ara h 1, 2 and 3) has been shown to
6
7 110 improve the specificity and sensitivity of diagnosing peanut allergy.^{16, 17} In BAMSE, children with IgE
8
9 111 reactivity to Ara h 1, 2 or 3 at age 8 years (but not Ara h 8) reported peanut allergic symptoms in
10
11 112 87% of cases, whereas children with IgE reactivity exclusively to Ara h 8 reported peanut allergic
12
13 113 symptoms in only 17% of cases which were also milder.¹⁸ Sweden has high levels of birch pollen
14
15 114 sensitization which explains the Bet v 1 in-vitro cross-reactivity with peanut Ara h 8;¹⁸⁻²⁰ thus, in this
16
17 115 study we differentiated between primary peanut sensitization (IgE reactivity to Ara h 1, 2 or 3) and
18
19 116 pollen cross-reactivity (IgE reactivity to Ara h 8).

20
21
22 117
23
24 118 This study aimed to assess whether EPE (as defined by peanut protein levels in household dust) is
25
26 119 a risk factor for the development of school-age peanut sensitization. The analysis was done in two
27
28 120 steps for financial and logistical reasons; firstly among high risk children (with parental atopy
29
30 121 matched to peanut sensitised cases), in a nested cases analysis and secondly among the whole
31
32 122 studied population (a cohort analysis). Given previous findings we also wanted to ascertain the
33
34 123 modifying effects of *FLG* loss-of-function mutations, infantile eczema and preceding egg
35
36 124 sensitization.

37
38 125
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods

The BAMSE study is an unselected Swedish population birth cohort. The design and methodology are described elsewhere.²¹ In brief 4089 unselected newborn children were recruited from 1994-1996 and have been evaluated for various health conditions over time. No intervention was performed. The BAMSE study obtained ethical approval for environmental sampling of dust.

Demographics

Serum specific IgE to peanut (ImmunoCAP system, ThermoFisher, Sweden) was measured at 4 and 8 years and children were defined as 'peanut sIgE sensitized' if peanut specific IgE was $\geq 0.35\text{kU/L}$. Peanut protein component allergens Ara h 1,2,3,8 and 9 were assessed at 8 years (ImmunoCAP system, ThermoFisher, Sweden) in all children sensitized to peanut at age 8 years, irrespective of sensitization to birch. In addition, those children who were peanut sensitized at age 4 years but lost their sensitization at age 8 were also analyzed for these allergens. All other children with negative peanut sIgE at age 8 years were assumed to have negative component allergens to peanut. Children were considered to have primary peanut sensitization if Ara h 1, 2 or 3 was $\geq 0.35\text{kU/L}$ and no primary peanut sensitization if Ara h 1, 2 and 3 were $< 0.35\text{kU/L}$ or peanut sIgE was $< 0.35\text{kU/L}$ at 8 years (where no sIgE peanut protein component allergens were available). Twenty-four (1.3%) children with positive peanut specific IgE at 8 years of age but with no available serum for peanut protein component allergen analysis were excluded from this analysis. Egg sensitization was defined as egg specific IgE $\geq 0.35\text{kU/L}$ at 4 years of age. Previous allergic reactions to a food including itching in the mouth, nose/eye problems, trouble breathing, vomiting or diarrhoea, eczema or nettle rash was used from parental questionnaires at age 8 years.

Parental atopy was defined as a doctor's diagnosis of asthma and prescription of asthma medication and/or a doctor's diagnosis of hay fever in combination with furred pets- and/or pollen allergy at the time of questionnaire. This definition of parental atopy was selected rather than the same definition with inclusion of a doctor's diagnosis of eczema (excluding contact dermatitis); this was because the children of parents with atopy including eczema were less atopic (lower infantile

1
2
3 153 eczema) and parental atopy including eczema was not associated with the outcome of interest
4
5 154 (primary peanut sensitization at 8 years of age); this is probably because adult eczema is often non-
6
7 155 atopic. Genotyping was performed for *FLG* mutations common in Scandinavia by using TaqMan
8
9 156 allelic discrimination assays for R501X and R2447X and matrix-assisted laser desorption/ionization-
10
11 157 time-of-flight mass spectrometry for 2282del4. Children with a *FLG* mutation in any of these
12
13 158 positions were classified as having a *FLG* loss-of function mutation.
14
15
16 159

17
18 160 A reported history of infantile eczema was assessed by a validated eczema questionnaire with
19
20 161 sensitivity of 92% and specificity of 100%.²² Eczema was defined as dry skin, itchy rashes for 2
21
22 162 weeks or more and age specific localization (face or arms/legs extension surfaces or arms/legs
23
24 163 flexures or wrists/ankles flexures) and/or doctor's diagnosis of eczema after 3 months and up to 1
25
26 164 year of age. Severity of eczema was assessed from questionnaires using three different measures:
27
28 165 1) Extent of localization of eczema (up to 10 areas) at or before their one year assessment
29
30 166 2) Topical steroids used as treatment for an itchy rash in the last year at their two year assessment
31
32 167 (not available at their one year assessment)
33
34 168 3) Persistent eczema at age 8 years (using the same definition as above).
35
36 169

37
38 170 Ethnicity was based on where the parents were born. Allergic rhinitis at 4 and 8 years was assessed
39
40 171 using International Study of Asthma and Allergies in Childhood (ISAAC) validated questionnaires,
41
42 172 and was defined as persistent rhinitis without a common cold the last 12 months before 4 and 8
43
44 173 years respectively.²³
45
46 174

47 48 49 175 **Dust collection methodology**

50
51 176 Dust samples were collected at a median of 2 months of age from the mother's mattress. The
52
53 177 mother's mattress was vacuumed for 2.5 minutes with a small disposable filter bag (Allergy Control
54
55 178 Products Inc. Ridgefield CT, USA) inserted in the front hose of the vacuum. The dust containing
56
57 179 filter bags were sealed in plastic bags and stored at -20°C. Dust samples were sieved and fine dust
58
59
60

was weighed and extracted in proportional volumes of extraction solution as previously described.²⁴ Peanut protein in dust was determined using the Veratox polyclonal ELISA against whole peanut protein (Neogen Corporation, Lansing, MI, USA). The lower limit of quantitation (LLQ) of the assay was defined as 100ng/ml and samples below this value were defined as 50ng/ml (LLQ/2).²⁵ Results were converted from ng/ml into µg peanut protein/gram dust. Due to batch to batch variability of the Veratox ELISA results were batch corrected prior to being entered into the final statistical analysis.

Statistical analysis

Data was entered into an SPSS (SPSS 19.0; SPSS Inc, Chicago, IL, USA) and STATA spreadsheet (Timberlake Consultants Ltd London, UK) for the purpose of analysis. Peanut protein levels in dust (µg/gram) underwent natural log transformation. Initial nested case control analysis was performed with peanut sIgE sensitized cases at 4 years of age matched for gender and parental atopy with a 2:1 control (n=274) to case (n=137) matching. Children with primary peanut sensitization defined by Ara h 1, 2 or 3 ≥0.35kU/L at 8 years of age were matched against controls at age 8 years with the same sex and level of parental atopy with a 2:1 ratio of controls (n=130) to cases (n=65). Given that these controls were matched for the higher levels of parental atopy in the primary peanut sensitized cases these controls were deemed to be high-risk as the primary peanut sensitized cases had higher levels of parental atopy than the population overall (46.7% vs. 32.6%). Conditional logistic regression (incorporating matching) was performed for the case control analysis using robust standard error for peanut sIgE sensitization at 4 years and primary peanut sensitization at age 8 years.

Subsequently analysis was performed for the relationship between early EPE and peanut sensitization in all children from the BAMSE cohort with available postnatal maternal bed-dust and *FLG* genotyping (n=1878). Logistic regression analysis was performed for primary peanut sensitization at 8 years of age. Factors associated with peanut sIgE sensitization were assessed using Generalized Estimating Equations (GEE) with an exchangeable working correlation matrix to

207 account for repeated measures within individuals at 4 and 8 years. Univariate followed by
208 multivariate regression analysis was performed including EPE plus other covariates significantly
209 associated with peanut sensitization ($P \leq .05$) which also improved the quality of fit of the multivariate
210 model using the Akaike information criterion (AIC) for logistic regression and the Quasi Likelihood
211 Independence models criterion (QIC) for GEE analyses.

212
213 Where the *FLG* mutation covariate was entered into the statistical model, participants with missing
214 ethnicity data (35/1878=1.9%) and non-caucasians (165/1842=8.8%) were excluded as distinct *FLG*
215 loss-of-function mutations are present in different populations and the *FLG* loss-of-function
216 mutations assessed in this study have only been associated with eczema in Caucasian European
217 populations^{26, 27} Peanut levels in dust ($\mu\text{g/g}$) were compared between groups using the Mann-
218 Whitney U test. Statistical significance was assessed at $P < .05$.

219

Results

Details of demographics and clinical characteristics included on this study are described in Table E1. Median peanut protein [IQR] in dust was 4.07µg/gram [1.58, 11.86]. Peanut extract sIgE sensitization was 6.6% at 4 years (n=103/1572) and 8.6% at 8 years (n=161/1876). Primary peanut sensitization at 8 years was 4.1% (n=75/1854), of which 74/75 (99%) had Ara h 2 ≥0.35kU/l. We first performed a nested case control analysis, and based on positive findings for this subsequently proceeded to then analyse the whole BAMSE cohort.

Nested case control analysis for peanut sIgE and primary peanut sensitization

We compared peanut sensitized children against children without peanut sensitization matched for gender and parental atopy as described in the statistical methods; EPE was a risk factor for both peanut extract sIgE sensitization at 4 years and primary peanut sensitization at 8 years with a 23% and 29% increased probability of developing peanut sensitization per natural log (*ln*) unit increase in EPE respectively (Table I). In children who were peanut extract sIgE sensitized but not sensitized to peanut protein component allergens Ara h 1, 2 and/or 3, there was only borderline significance towards an association between EPE and peanut sensitization (OR=1.20, 95% CI: 0.97-1.48).

Differential relationship between EPE and primary peanut sensitization and non-clinically significant peanut sensitization is displayed in Figure 1. Median peanut protein in dust was higher in peanut extract sIgE sensitized children (3.39 µg/g, IQR 1.41-11.01, n=137) than non-peanut extract sIgE sensitized controls (2.28µg/g, IQR 0.88-5.14, n=274) (*P*<.01); and higher in primary peanut sensitized children (4.64µg/g, IQR 1.58-12.77, n=65) than in control children that were not sensitized to Ara h 1,2 or 3 (2.24µg/g, IQR 0.88-4.74, n=130) (*P*<.01).

On multivariate conditional logistic regression analysis, EPE was significantly associated with peanut specific IgE and primary peanut sensitization with a 1.41- and 2.1-fold increased probability

of developing peanut sensitization per unit increase EPE respectively (Table II). Infantile eczema and egg sensitization were both significantly associated with sensitization to peanut extract and sensitization to peanut protein component allergens Ara h 1, 2 and/or 3.(Table II). *FLG* loss-of-function mutations increased the probability of developing peanut specific IgE sensitization 3.78-fold and primary peanut sensitization 7.33-fold. Allergic rhinitis at age 4 and 8 years was associated with both the probability of developing peanut specific IgE sensitization at age 4 years and primary peanut sensitization at age 8 years in the multivariate analysis. The number of biological siblings, duration of exclusive and total breastfeeding and maternal age at baseline were not associated with peanut sensitization. There was no significant interaction between EPE and either infantile eczema, egg sensitization or *FLG* loss-of-function mutations on primary peanut sensitization (data not shown).

257

258 **Whole cohort analysis for peanut extract sIgE sensitization and primary peanut sensitization**

In a second step following positive findings obtained on case control analysis, we assessed the relationship between early EPE and peanut sensitization in all children from the BAMSE cohort with available postnatal maternal bed-dust and *FLG* genotyping (n=1878). On both univariate (Table III) and multivariate analysis (Table IV) infantile eczema, egg sensitization at age 4 years, tree nut and soya allergy at age 8 years, *FLG* loss-of function mutation and allergic rhinitis at age 8 years were associated with the probability of peanut sIgE sensitization at age 4 and 8 years. For primary peanut sensitization at age 8 significant associations were also seen on univariate (Table III) and multivariate analysis (Table IV) for infantile eczema, egg sensitization, tree nut and soya allergy at age 8 years and allergic rhinitis at age 8 years. Although measures of eczema severity and several other food allergies at age 8 years were significantly association with peanut sensitization on univariate analysis, these variables were no longer significantly associated on multivariate analysis. EPE was not associated with peanut sIgE sensitization or primary peanut sensitization. There was no interaction between EPE and *FLG* mutations, infantile eczema, egg sensitization, allergic reaction to tree nut or soya by age 8 years, or parental atopy on peanut sensitization.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

273

274 **Subgroup analysis of primary peanut sensitization against egg sensitized non peanut**

275 **allergic individuals**

276 On subgroup analysis we compared primary peanut sensitized children (n=75) against children who

277 were sensitized to egg (slgE≥0.35kU/L at age 4 years) but did not go on to have primary peanut

278 sensitization at age 8 years (n=59). EPE increased the probability of primary peanut sensitization on

279 both univariate (OR=1.33 95% CI:1.01-1.74, *P*<.05, n=134) (Table V) and multivariate analysis

280 (OR=1.44, 95% CI:1.06-1.94, *P*0.018, n=133, AIC: 167) adjusting for infantile eczema and allergic

281 reaction to soya by age 8 years. Peanut levels in household dust were also significantly higher in

282 primary peanut sensitized children (median 4.79µg/g, IQR 1.63-12.00) versus egg sensitized, non-

283 primary peanut sensitized children (median 2.35µg/g, IQR 1.23-6.15) (*P*=.03). We assessed the

284 impact of EPE on peanut sensitization when using other high-risk groups of children who were not

285 peanut sensitized at age 8 years (*FLG* mutations, infantile eczema, soya allergy and parental atopy)

286 and there was no significant association.

287

Discussion

In the prospective birth cohort BAMSE, there was an exposure-response relationship between EPE (quantified using peanut protein levels from maternal mattress-dust postnatally) and primary peanut sensitization (Ara h 1, 2 or 3 ≥ 0.35 kU/L) among high risk children (in a nested cases analysis). When all children in the whole studied population were assessed, there was no association between EPE and peanut sensitization; however, on subgroup analysis there was an exposure-response relationship between EPE and primary peanut sensitization when compared against high risk egg sensitized children. Fox et al. also showed that household peanut consumption during the first year of life (as an indirect marker of EPE) was higher in peanut allergic cases than in egg allergic controls.¹³ In the nested cases analysis the exposure-response relationship was stronger between EPE and primary peanut sensitization (Ara h 1,2 or 3 ≥ 0.35 kU/L) than between EPE and non-clinically relevant peanut sensitization (peanut sIgE ≥ 0.35 kU/L but negative results for Ara h 1,2 or 3 < 0.35 kU/L) (Figure 1). This supports the concept that EPE increases the probability of developing clinically relevant peanut sensitization which is more likely to develop into peanut allergy rather than non-specific peanut sensitization.

In other cohorts we have shown a synergistic effect between EPE and markers of an impaired skin barrier (infantile eczema and *FLG* loss-of-function mutations) on peanut sensitization and allergy.¹¹

¹² Although in BAMSE we did not find significant interactions between EPE and *FLG* mutations or infantile eczema on peanut sensitization, we did show on subgroup analysis that early EPE has more impact on the probability of developing peanut sensitization when compared against high risk children (defined by parental atopy in the nested cases analysis and egg sensitization in the whole cohort analysis) than in children without these risk factors. The BAMSE cohort is relatively non-atopic, being from the general population in Sweden, which may have contributed to lower strength of associations between EPE and atopic markers. The median level of peanut protein in maternal bed-dust dust in the BAMSE cohort was 4.07 μ g/gram [IQR 1.58, 11.86], similar to that found in another the UK study by our group (median 4.19 IQR 0.54-24.89).²⁴ The level of peanut in dust was higher in a US study that measured peanut from the living room floor (median 39.1 μ g/g IQR 0.4-

1
2
3 316 1.33).⁽¹⁰⁾ It would; however, be expected that peanut levels would be higher in America due to
4
5 317 higher levels of peanut consumption.
6
7
8 318
9
10 319 Infantile eczema was one of the most important risk factors for peanut sensitization in BAMSE; this
11
12 320 association has been cited in numerous studies.^{8, 28} Measures of eczema severity (extent of
13
14 321 localisation, topical steroid use and persistent eczema) were associated with peanut sensitization on
15
16 322 univariate analysis but were no longer associated on multivariate analysis. Eczema severity has
17
18 323 previous been shown to be an independent risk factor for food sensitization in the EAT (Enquiring
19
20 324 About Tolerance) study.²⁹ The EAT study used the SCORAD eczema severity scoring system;
21
22 325 however, this could not be performed in the BAMSE study as the evaluations at 1, 2, 4 and 8 years
23
24 326 were based on parental questionnaires.
25
26 327
27
28 328 Egg sensitization was highly associated with peanut sensitization; which has previously been shown
29
30 329 in numerous cohort studies;^{11, 12, 30} it may be that egg sensitization shows a predisposition to mount
31
32 330 allergic antibodies to other allergens as egg allergy is highly associated with the development of
33
34 331 other food allergies, asthma and aeroallergen sensitization.^{31, 32} Observational studies have shown
35
36 332 that in children with severe, early onset eczema, up to 50% are sensitized to egg;²⁸ thus egg
37
38 333 sensitization may be an additional marker of eczema severity. *FLG* loss-of-function mutations were
39
40 334 less important than infantile eczema in predicting the development of peanut sensitization, and *FLG*
41
42 335 mutations became more important if infantile eczema was not included in the regression model.
43
44 336 Previous studies have found that children that carry a *FLG* mutation have an increased risk of
45
46 337 peanut allergy even after adjusting for eczema.³³ In this study eczema seemed to be the overriding
47
48 338 factor for peanut sensitization; however, it should be noted that *FLG* mutations were quite low in
49
50 339 BAMSE (7.14%) in comparison with other population-based cohorts.^{26, 33, 34} Tree nut and/or soya
51
52 340 allergy by age 8 was also associated with primary peanut sensitization at age 8 years; co-existent
53
54 341 peanut and tree-nut allergy has been shown in numerous studies,^{35, 36} whereas co-existent soya and
55
56 342 peanut allergy is reportedly low.³⁷
57
58
59
60

343

344 Strength of the present study includes the population based design and relatively high number of

345 study participants. Limitations of this study included the lack of diagnostic food challenges to

346 determine peanut allergy as the BAMSE study was not originally designed to evaluate peanut

347 allergic outcomes; however, primary peanut sensitization has been shown to be a much more

348 accurate predictor of clinically confirmed peanut allergy than peanut specific IgE.^{38, 39} Certain

349 potential confounders were not available such as parental peanut allergy or other parental food

350 allergies, maternal peanut consumption during pregnancy and breast-feeding and infant peanut

351 consumption. Therefore we are unable to assess whether infant peanut consumption could have

352 protected the children against environmental exposure to peanut as has been shown in previous

353 studies;^{13, 35} however, when BAMSE was recruiting participants in 1996 the number of infants eating

354 peanut was very low. Caucasian ethnicity was based on place of parental birth rather than self-

355 reported ethnicity; however, when the BAMSE study was recruiting participants 1994-1996, most

356 parents born in Sweden or Northern Europe would have been of Caucasian descent.⁴⁰ Findings on

357 case control analysis could not be replicated on whole cohort analysis; therefore, these findings

358 need to be confirmed in other population based cohorts.

359

360 Conclusion

361 In summary, although EPE did not increase the risk of peanut sensitization in children who did not

362 already have atopic risk factors, the findings from the BAMSE cohort support the hypothesis that in

363 specific high risk groups, peanut levels in dust around the time of birth may pose a risk for later

364 peanut sensitization. Further prospective studies are needed to confirm these findings in other

365 populations.

366

367 Acknowledgement

368 We wish to thanks Dr Alick Stephens for his assistance in the BAMSE dust analysis. The authors

369 thank all children and their parents in the BAMSE cohort

1
2
3 370
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Table EI: Demographics of whole studied BAMSE population with available dust and *FLG* genotyping (n=1878)

	Number of cases	No. data points	Percentage of cases / no. of available data points
Peanut specific IgE ≥ 0.35 kU/L at 4 years	103	1572	6.55%
Peanut specific IgE ≥ 0.35 kU/L at 8 years	161	1876	8.58%
Ara h 1, 2 or 3 ≥ 0.35 kU/L at 8 years vs. Ara h 1, 2 or 3 < 0.35 kU/L or peanut sIgE < 0.35 kU/L (excluding peanut sIgE ≥ 0.35 kU/L with no components or missing data) at 8 yrs	75	1854	4.05%
History of infantile atopic dermatitis	313	1840	17.01%
Topical steroid use between age 1-2 years	534	1842	29.0%
Higher extent of localisation of eczema (>5 areas vs. <5 areas or no eczema)	49	1841	2.7%
Persistent eczema at age 8 years	321	1828	17.6%
At least one <i>FLG</i> mutation (R501X, 2282del or R2447x)	134	1878	7.14%
Allergic rhinitis (ISAAC definition) (age 4 years)	215	1828	11.76%
Allergic rhinitis (ISAAC definition) (age 8 years)	288	1865	15.44%
Egg sIgE ≥ 0.35 IU/ml at 4 years of age	82	1575	5.21%
Reported allergic reaction to any food 8 years	349	1869	18.7%
Reported allergic reaction to peanut by 8 years	120	1869	6.4%
Reported allergic reaction to milk by 8 years	53	1869	2.8%
Reported allergic reaction to egg by 8 years	36	1869	1.9%
Reported allergic reaction to fish by 8 years	12	1869	0.6%
Reported allergic reaction to shellfish 8 years	17	1869	0.9%
Reported allergic reaction to wheat by 8 years	9	1869	0.5%
Reported allergic reaction to soya by 8 years	21	1869	1.1%
Reported allergic reaction to apple by 8 years	83	1869	4.4%
Reported allergic reaction to peach by 8 years	44	1869	2.4%
Reported allergic reaction to kiwi by 8 years	92	1869	4.9%
Reported allergic reaction to avocado 8 years	14	1869	0.7%

Reported allergic reaction to banana by 8 years	17	1869	0.9%
Reported allergic reaction to carrot by 8 years	53	1869	2.8%
Reported allergic reaction to tree nuts 8 years	105	1869	5.6%
Male gender	973	1871	52.00%
Caucasian ethnicity	1677	1842	91.04%
Biological siblings	1695	1870	90.64%
Parental atopy – (asthma/AR/eczema)	838	1858	45.10%
Parental atopy – (asthma/AR)	605	1856	32.60%
Maternal age (mean, SD)	30.9 (SD 4.49)	1871	N/A
Peanut protein in maternal bed-dust (µg/g): median [IQR]	4.07 [1.58-11.86]	1878	N/A
Exclusive breast-feeding duration (months): mean (SD)	5.19 (2.43)	1838	N/A
Total breast-feeding duration (months): mean (SD)	8.73 (3.31)	1825	N/A

373

Table I: Univariate conditional logistic regression incorporating matching for peanut sensitized cases versus non-sensitized controls matched for gender and parental atopy. Peanut sIgE sensitization (≥ 0.35 kU/L) at age 4 years and primary peanut sensitization (Ara h 1, 2 or 3 ≥ 0.35 kU/L) at age 8 years.

	Peanut sIgE sensitized at age 4 years (n=411)			Peanut PAM sensitized at age 8 years (n=195)		
	OR	95% CI	P value	OR	95% CI	P-value
EPE (μ g/gram ln transformed)	1.23	1.06-1.43	<.01	1.29	1.04-1.61	.02
No. of biological siblings	1.38	0.63-3.03	.42	2.50	0.77-8.16	.13
≥ 1 <i>FLG</i> loss-of-function mutation (excluding non-caucasians)	2.67	1.18-6.04	.02	3.00	0.84-10.75	.09
History of infantile eczema	7.35	4.20-12.83	<.001	6.39	2.95-13.83	<.001
Egg sIgE sensitization: 4 years	18.91	7.50-47.66	<.001	12.85	3.78-43.67	<.001
*Allergic rhinitis: 4 years (ISAAC)	3.44	1.90-6.23	<.001	2.53	1.04-6.18	.04
*Allergic rhinitis: 8 years (ISAAC)	11.44	5.68-23.07	<.001	12.97	4.54-37.05	<.001
Exclusively breastfed (months)	0.95	0.88-1.03	.22	0.98	0.87-1.11	.77
Breastfed (excl/partial) (months)	0.99	0.93-1.05	.74	1.01	0.93-1.11	.76
Maternal age at baseline (in years)	0.99	0.94-1.04	.65	1.05	0.99-1.12	.12

*Allergic rhinitis was included to assess whether false positive results for peanut sensitization were being found due to cross-reactivity with grass or tree pollens.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table II: Multivariate conditional logistic regression incorporating matching for peanut sensitized cases versus non-sensitized controls matched for gender and parental atopy. Peanut sIgE sensitization (≥ 0.35 kU/L) at age 4 years and primary peanut sensitization (Ara h 1, 2 or 3 ≥ 0.35 kU/L) at age 8 years. Non-caucasians were excluded due to inclusion of *FLG* mutations as a covariate.

	Peanut sIgE sensitized at age 4 years (excluding non-caucasians) (n=237)			Primary peanut sensitization at age 8 years (excluding non-caucasians) (n=143)		
	*AIC: 90.78			*AIC: 49.19		
	OR	95% CI	P Value	OR	95% CI	P Value
EPE (μ g/gram ln transformed)	1.41	1.05-1.90	.02	2.11	1.38-3.22	.001
≥ 1 <i>FLG</i> loss-of-function mutation	3.78	0.93-15.36	.06	7.33	1.21-44.21	.03
History of infantile eczema	2.53	0.98-6.51	.05	3.93	1.03-15.00	.05
Egg sIgE sensitization: 4 years	28.00	5.24-149.39	<.001	39.9	1.47-1081.68	.03
**Allergic rhinitis: 8 years (ISAAC)	12.57	4.164-37.98	<.001	28.93	3.77-221.61	<.001

*Smaller AIC is better. **Allergic rhinitis at age 8 years was selected as it improved the fit of the model (AIC better than allergic rhinitis at age 4 years).

Table III: Univariate analysis of peanut specific IgE sensitization aged 4 and 8 years using GEE to account for repeated measures within individuals at 4 and 8 years and logistic regression for primary peanut sensitization at age 8 years in the whole BAMSE cohort (n=1878).

	GEE for peanut sIgE			Univariate primary peanut sensitization at age 8 years		
	OR	95% CI	P Value	OR	95% CI	P Value
EPE ($\mu\text{g}/\text{gram}$ ln transformed)	0.95	0.86-1.06	0.39	1.01	0.86-1.19	.89
Gender	1.14	0.83-1.56	0.43	1.41	0.88-2.26	.15
Full older siblings	1.08	0.63-1.85	0.77	0.86	0.40-1.81	0.68
≥ 1 <i>FLG</i> loss-of-function mutations	1.84	1.10-3.05	0.02	1.84	0.89-3.77	0.10
Questionnaire based history of infantile eczema	6.49	4.66-9.02	<.001	7.94	4.91-12.83	<.001
Localisation of infantile eczema (continuous 1-10 areas/per unit)	1.48	1.37-1.59	<.001	1.53	1.40-1.68	<.001
Localisation of infantile eczema (<5 areas vs. 5+ areas)	7.69	4.26-13.55	<.001	10.4	5.24-20.65	<.001
Application of topical steroids for itchy rash (1-2 yrs)	3.24	2.35-4.46	<.001	3.95	2.46-6.34	<.001
Persistent eczema at age 8 years	3.87	2.76-5.44	<.001	2.85	1.69-4.81	<.001
Egg sIgE sensitization at 4 years	13.58	8.55-21.58	<.001	11.04	6.13-19.90	<.001
Allergic reaction to milk by 8 years	5.68	3.12-10.34	<.001	4.24	1.84-9.77	0.001
Allergic reaction to egg by 8 years	26.81	13.98-51.4	<.001	16.67	7.81-35.59	<.001
Allergic reaction to fish by 8 years	17.25	5.41-54.96	<.001	9.18	2.39-35.32	0.001
Allergic reaction to shellfish 8 years	15.59	6.07-40.02	<.001	3.70	0.82-16.71	0.09
Allergic reaction to wheat by 8 years	9.55	2.53-36.02	0.001	8.06	1.60-40.59	0.01
Allergic reaction to soya by 8 years	48.75	17.61-134.97	<.001	41.95	16.56-106.24	<.001

Allergic reaction to apple by 8 years	12.54	8.16-19.27	<.001	5.93	3.15-11.13	<.001
Allergic reaction to peach by 8 years	14.37	8.15-25.34	<.001	6.49	2.88-14.61	<.001
Allergic reaction to kiwi by 8 years	5.95	3.80-9.31	<.001	4.25	2.20-8.20	<.001
Allergic reaction to avocado 8 years	12.27	4.61-32.66	<.001	4.38	0.95-20.13	0.06
Allergic reaction to banana 8 years	12.19	5.07-29.30	<.001	3.44	0.77-15.40	0.11
Allergic reaction to carrot by 8 years	17.84	10.6-30.05	<.001	7.83	3.83-16.03	<.001
Allergic reaction to tree nuts 8 years	21.93	14.45-33.28	<.001	10.29	12.08-34.05	<.001
Allergic rhinitis aged 4 years	2.82	1.92-4.13	<.001	2.16	1.22-3.83	0.008
Allergic rhinitis aged 8 years	8.05	5.78-11.22	<.001	5.87	3.66-9.42	<.001
Parental atopy (asthma and/or AR)	1.77	1.28-2.44	<.001	1.77	1.10-2.83	0.018
Parental atopy (asthma, AR,eczema)	1.44	1.05-1.98	0.02	1.50	0.95-2.39	0.09
Non-caucasian ethnicity	1.58	0.97-2.57	0.07	1.09	0.49-2.43	0.79
Exclusively breastfed in months	0.98	0.94-1.06	0.92	0.97	0.88-1.06	0.49
Breastfed (exclusive/partial) in mo	0.99	0.94-1.03	0.57	0.97	0.91-1.04	0.43
Maternal age at baseline (in years)	1.02	0.98-1.05	0.44	1.02	0.97-1.07	0.53

391

Table IV: Multivariate analysis of peanut specific IgE sensitization aged 4 and 8 years using generalised estimating equations (GEE) to account for repeated measures within individuals at 4 and 8 years and logistic regression analysis for primary peanut sensitization at age 8 years in the BAMSE cohort, Goodness of fit assessed by QIC and AIC.

	Multivariate peanut sIgE sensitization (excluding non-caucasians) (1367) QIC:935			Multivariate primary peanut sensitization (n=1521) AIC:386		
	OR	95% CI	P Value	OR	95% CI	P Value
EPE ($\mu\text{g}/\text{gram}$ ln transformed)	0.94	0.80-1.11	.45	1.08	0.87-1.34	.48
≥ 1 FLG loss-of-function mutations	2.52	1.24-5.10	0.01		ns*	
History of infantile eczema	2.75	1.67-4.48	<.001	4.02	2.14-7.54	<.001
Tree nut allergic reaction by age 8 years	9.30	4.94-17.53	<.001	4.80	2.38-9.66	<.001
Soya allergic reaction by age 8 years	18.21	4.75-69.80	<.001	2.54	3.85-42.07	<.001
Egg sIgE sensitization at 4 years	7.66	3.92-14.95	<.001	4.24	1.98-9.09	<.001
Allergic rhinitis aged 8 years (ISAAC)	4.02	2.49-6.52	<.001	2.01	1.05-3.83	0.034

*ns: Not significant on multivariate analysis therefore not included in final multivariate analysis.

Table V: Univariate analysis of factors associated with primary peanut sensitization (at age 8 years) versus non primary peanut sensitization (at age 8 years) in high risk children with preceding egg sensitization (at age 4 years) (n=134).

	Primary peanut sensitization vs. non-peanut sensitized egg sensitized controls		
	OR	95% CI	P Value
EPE (µg/gram in transformed)	1.33	1.01-1.74	<0.05
Gender	1.90	0.95-3.80	0.07
Full older siblings	0.61	0.17-2.13	0.44
≥1 <i>FLG</i> loss-of-function mutations (excluding non-caucasians)	1.09	0.33-3.56	0.89
History of infantile eczema	2.51	1.24-5.08	0.01
Localisation of infantile eczema (continuous 1-10 areas/per unit)	1.15	1.01-1.32	0.04
Localisation of infantile eczema (<5 areas vs. 5+ areas)	1.36	0.52-3.53	0.53
Application of topical steroids for itchy rash (1-2 yrs)	1.40	0.70-2.80	0.34
Persistent eczema at age 8 years	2.32	1.09-4.90	0.03
Allergic reaction to milk by 8 years	1.42	0.39-5.09	0.59
Allergic reaction to fish by 8 years	0.78	0.15-4.00	0.78
Allergic reaction to shellfish 8 years	0.30	0.06-1.58	0.16
Allergic reaction to wheat by 8 years	1.59	0.14-17.96	0.71
Allergic reaction to soya by 8 years	11.05	1.39-87.63	0.02
Allergic reaction to apple by 8 years	1.71	0.64-4.52	0.29
Allergic reaction to peach by 8 years	1.29	0.40-4.17	0.67
Allergic reaction to kiwi by 8 years	1.42	0.52-3.85	0.50
Allergic reaction to avocado 8 years	0.78	0.11-5.71	0.81

Allergic reaction to banana 8 years	0.38	0.07-2.13	0.27
Allergic reaction to carrot by 8 years	2.36	0.71-7.85	0.16
Allergic reaction to tree nuts 8 years	3.43	1.54-7.62	0.002
Allergic rhinitis aged 4 years (ISAAC)	0.87	0.38-1.96	0.73
Allergic rhinitis aged 8 years (ISAAC)	2.65	1.26-5.56	0.01
Parental atopy (asthma/ and /or hay-fever)	1.34	0.67-2.65	0.41
Non-caucasian ethnicity	2.55	0.93-6.98	0.07
Exclusively breastfed in months	0.89	0.77-1.04	0.14
Breastfed (exclusive/partial) in months	0.99	0.89-1.09	0.76
Maternal age at baseline (in years)	1.06	0.99-1.14	0.11

400

401

Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Legend

Figure 1: Mean predictive probability of peanut sensitization in children with primary peanut sensitization (Ara h 1,2 or 3 ≥ 0.35 kU/L) versus children with peanut specific IgE ≥ 0.35 kU/L but with negative results for primary peanut (Ara h 1,2 or 3 < 0.35 kU/L).

Contributions of each author

HB, IK, EH, MW, GL had substantial contributions to the conception and design of the study. HB, KM, MP and VR made substantial contributions to acquisition of peanut-dust data and analysis. HB and AD performed the statistical analysis of results. IK, EH, CS, AB, EM and MW had substantial contribution to the BAMSE study and obtaining data to perform this study. CS performed the FLG genotyping. All authors contributed to the drafting and revising the manuscript for intellectual content and have approved the version to be published.

Conflict of interests

H. A. Brough has received research support, lecture fees, and travel support from ThermoFisher Scientific. G. Lack and V. Turcanu have received research support from the National Peanut Board. I Kull, K Makinson, E Hallner, C Söderhäll, A Douiri, M Penagos, E Melén, A Bergström and M Wickman declare that they have no relevant conflicts of interest.

References

1. Venter C, Hasan AS, Grundy J, Pereira B, Bernie CC, Voigt K, et al. Time trends in the prevalence of peanut allergy: three cohorts of children from the same geographical location in the UK. *Allergy* 2010; 65:103-8.
2. Sicherer SH, Munoz-Furlong A, Godbold JH, Sampson HA. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. *J Allergy Clin Immunol* 2010; 125:1322-6.
3. Bock SA, Munoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. *J Allergy Clin Immunol* 2007; 119:1016-8.
4. Avery NJ, King RM, Knight S, Hourihane JOB. Assessment of quality of life in children with peanut allergy. *Pediatr Allergy Immunol* 2003:378-82.
5. King RM, Knibb RC, Hourihane JO. Impact of peanut allergy on quality of life, stress and anxiety in the family. *Allergy* 2009; 64:461-8.
6. Hourihane JOB, Kilburn SA, Dean P, Warner JO. Clinical characteristics of peanut allergy. *Clin Exp Allergy* 1997; 27:634-9.
7. Monti G, Muratore MC, Peltran A, Bonfante G, Silvestro L, Oggero R, et al. High incidence of adverse reactions to egg challenge on first known exposure in young atopic dermatitis children: predictive value of skin prick test and radioallergosorbent test to egg proteins. *Clin Exp Allergy* 2002; 32:1515-9.
8. Lack G, Fox D, Northstone K, Golding J, Team ALSoPaCS. Factors associated with the development of peanut allergy in childhood. *N Engl J Med* 2003; 348:977-85.
9. Strid J, Hourihane J, Kimber I, Callard R, Strobel S. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. *Eur J Immunol* 2004; 34:2100-9.
10. Reynolds LA, Finlay BB. Early life factors that affect allergy development. *Nat Rev Immunol* 2017.
11. Brough HA, Simpson A, Makinson K, Hankinson J, Brown S, Douiri A, et al. Peanut allergy: effect of environmental peanut exposure in children with filaggrin loss-of-function mutations. *J Allergy Clin Immunol* 2014; 134:867-75 e1.
12. Brough HA, Liu AH, Sicherer S, Makinson K, Douiri A, Brown SJ, et al. Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy. *J Allergy Clin Immunol* 2015; 135:164-70.
13. Fox AT, Sasieni P, Du Toit G, Syed H, Lack G. Household peanut consumption as a risk factor for the development of peanut allergy. *J Allergy Clin Immunol* 2009; 123:417-23.

1
2
3 457 14. Garcia-Boyano M, Pedrosa M, Quirce S, Boyano-Martinez T. Household almond and peanut
4 458 consumption is related to the development of sensitization in young children. *J Allergy Clin*
5 459 *Immunol* 2016; 137:1248-51.
6 460 15. Brough HA, Santos A, Makinson K, Penagos M, Stephens AC, Fox AT, et al. Peanut protein
7 461 in household dust is related to household peanut consumption and is biologically active. *J*
8 462 *Allergy Clin Immunol* 2013; 132:630-8.
9 463 16. Nicolaou N, Murray C, Belgrave D, Poorafshar M, Simpson A, Custovic A. Quantification of
10 464 specific IgE to whole peanut extract and peanut components in prediction of peanut allergy.
11 465 *J Allergy Clin Immunol* 2011; 127:684-5.
12 466 17. Dang TD, Tang M, Choo S, Licciardi PV, Koplin JJ, Martin PE, et al. Increasing the accuracy
13 467 of peanut allergy diagnosis by using Ara h 2. *J Allergy Clin Immunol* 2012; 129:1056-63.
14 468 18. Asarnoj A, Ostblom E, Kull I, Lilja G, Pershagen G, Hedlin G, et al. Sensitization to inhalant
15 469 allergens between 4 and 8 years of age is a dynamic process: Results from the BAMSE birth
16 470 cohort. *Clin Exp Allergy* 2008; 1507-13.
17 471 19. Asarnoj A, Ostblom E, Ahlstedt S, Hedlin G, Lilja G, van HM, et al. Reported symptoms to
18 472 peanut between 4 and 8 years among children sensitized to peanut and birch pollen - results
19 473 from the BAMSE birth cohort. *Allergy* 2010; 65:213-9.
20 474 20. Asarnoj A, Hamsten C, Lupinek C, Melen E, Andersson N, Anto JM, et al. Prediction of
21 475 peanut allergy in adolescence by early childhood storage protein-specific IgE signatures:
22 476 The BAMSE population-based birth cohort. *J Allergy Clin Immunol* 2017.
23 477 21. Wickman M, Kull I, Pershagen G, Nordvall SL. The BAMSE project: presentation of a
24 478 prospective longitudinal birth cohort study. *Pediatr Allergy Immunol* 2002; 13:Suppl-3.
25 479 22. Bohme M, Lannero E, Wickman M, Nordvall SL, Wahlgren CF. Atopic dermatitis and
26 480 concomitant disease patterns in children up to two years of age. *Acta Derm Venereol* 2002;
27 481 82:98-103.
28 482 23. Strachan D, Sibbald B, Weiland S, Ait-Khaled N, Anabwani G, Anderson HR, et al.
29 483 Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the
30 484 International Study of Asthma and Allergies in Childhood (ISAAC). *Pediatr Allergy Immunol*
31 485 1997; 8:161-76.
32 486 24. Brough HA, Makinson K, Penagos M, Maleki SJ, Cheng H, Stephens AC, et al. Distribution
33 487 of peanut protein in the home environment. *J Allergy Clin Immunol* 2013; 132:623-9.
34 488 25. RW H, LD R. Estimation of average concentration in the presence of nondetectable values.
35 489 *App Occup Environ Hyg* 1990; 5:46-51.
36 490 26. Baurecht H, Irvine AD, Novak N, Illig T, Buhler B, Ring J, et al. Toward a major risk factor for
37 491 atopic eczema: Meta-analysis of filaggrin polymorphism data. *J Allergy Clin Immunol* 2007;
38 492 120:1406-12.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 493 27. Weidinger S, O'Sullivan M, Illig T, Baurecht H, Depner M, Rodriguez E, et al. Filaggrin
4 494 mutations, atopic eczema, hay fever, and asthma in children. *J Allergy Clin Immunol* 2008;
5 495 121:1203-9.
6
7 496 28. Hill DJ, Hosking CS, Oranje AP, Bauchau V, Naspitz CK, Simons FER, et al. Confirmation of
8 497 the association between high levels of immunoglobulin E food sensitization and eczema in
9 498 infancy: An international study. *Clin Exp Allergy* 2008; 38:161-8.
10
11 499 29. Flohr C, Perkin M, Logan K, Marrs T, Radulovic S, Campbell LE, et al. Atopic dermatitis and
12 500 disease severity are the main risk factors for food sensitization in exclusively breastfed
13 501 infants. *J Invest Dermatol* 2014; 134:345-50.
14
15 502 30. Du Toit G, Roberts G, Sayre PH, Plaut M, Bahnson HT, Mitchell H, et al. Identifying infants
16 503 at high risk of peanut allergy: the Learning Early About Peanut Allergy (LEAP) screening
17 504 study. *J Allergy Clin Immunol* 2013; 131:135-43 e1-12.
18
19 505 31. Tariq SM, Matthews SM, Hakim EA, Arshad SH. Egg allergy in infancy predicts respiratory
20 506 allergic disease by 4 years of age. *Pediatric Allergy & Immunology* 2000; 11:162-7.
21
22 507 32. Gaffin JM, Sheehan WJ, Morrill J, Cinar M, Borrás Coughlin IM, Sawicki GS, et al. Tree nut
23 508 allergy, egg allergy, and asthma in children. *Clin Pediatr* 2011; 50:133-9.
24
25 509 33. Brown SJ, Asai Y, Cordell HJ, Campbell LE, Zhao Y, Liao H, et al. Loss-of-function variants
26 510 in the filaggrin gene are a significant risk factor for peanut allergy. *J Allergy Clin Immunol*
27 511 2011; 127:661-7.
28
29 512 34. Johansson EK, Bergstrom A, Kull I, Lind T, Soderhall C, van Hage M, et al. IgE sensitization
30 513 in relation to preschool eczema and filaggrin mutation. *J Allergy Clin Immunol* 2017.
31
32 514 35. Du Toit G, Katz Y, Sasieni P, Mesher D, Maleki SJ, Fisher HR, et al. Early consumption of
33 515 peanuts in infancy is associated with a low prevalence of peanut allergy. *J Allergy Clin*
34 516 *Immunol* 2008; 122:984-91.
35
36 517 36. Sicherer SH, Munoz-Furlong A, Sampson HA. Prevalence of peanut and tree nut allergy in
37 518 the United States determined by means of a random digit dial telephone survey: a 5-year
38 519 follow-up study. *J Allergy Clin Immunol* 2003; 112:1203-7.
39
40 520 37. Sampson HA, McCaskill CC. Food hypersensitivity and atopic dermatitis: evaluation of 113
41 521 patients. *J Pediatr* 1985; 107:669-75.
42
43 522 38. Nicolaou N, Poorafshar M, Murray C, Simpson A, Winell H, Kerry G, et al. Allergy or
44 523 tolerance in children sensitized to peanut: prevalence and differentiation using component-
45 524 resolved diagnostics. *J Allergy Clin Immunol* 2010; 125:191-7.
46
47 525 39. Beyer K, Grabenhenrich L, Hartl M, Beder A, Kalb B, Ziegert M, et al. Predictive values of
48 526 component-specific IgE for the outcome of peanut and hazelnut food challenges in children.
49 527 *Allergy* 2015; 70:90-8.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

528 40. Besharat PM, Bergstrom A, Bottai M, Kull I, Wickman M, Hakansson N, et al. Effect of
529 parental migration background on childhood nutrition, physical activity, and body mass
530 index. J Obesity 2014; 2014:406529.
531

For Peer Review

Environmental peanut exposure increases the risk of peanut sensitization in high risk children

Helen A. Brough FRCPCH PhD*,^{1,2} Inger Kull PhD*,^{3,4,5} Kerry [Richards](#) MSc,¹ Eva Hallner,³ Cilla Söderhäll PhD,^{6,7,8} Abdel Douiri PhD,⁹ Martin Penagos MD MSc,¹ Erik Melén,^{3,5} Anna Bergström,^{3,7} Victor Turcanu PhD,¹ Magnus Wickman MD PhD**,³ Gideon Lack MD FRCPCH**,^{1,2}

¹ Paediatric Allergy, Department of Asthma, Allergy and Respiratory Science, Division of Asthma Allergy and Lung Biology, MRC & Asthma UK Centre for the Allergic Mechanisms of Asthma, King's College London, Guys' Hospital, London, SE1 9RT, UK

² Children's Allergy Service, Guy's and St. Thomas's NHS Foundation Trust, Westminster Bridge Rd, London SE1 7EH.

³ Institute of Environmental Medicine, Karolinska Institutet, [Stockholm, Sweden](#) and

⁴ Centre for Occupational and Environmental Medicine, Stockholm County Council, Stockholm, Sweden

⁵ Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden

⁶ Sachs' Children's Hospital, Södersjukhuset, Stockholm, Sweden

⁷ Department of Biosciences and Nutrition, Karolinska Institutet, 141 83 Stockholm, Sweden

⁸ Centre of Allergy Research, Karolinska Institutet, Stockholm, Sweden

⁹ Department of Women's and Children's Health, Karolinska Institutet, 171 77 Stockholm, Sweden

^{9a} [Division of Health & Social Care Research, King's College London, Addison House, Guy's Campus, London SE1 1UL, UK](#) ~~Department of Medical Statistics, Public Health School of Medicine, King's College London, Guys' Hospital, London, SE1 9RT, UK~~

* These authors contributed equally to the manuscript and are joint first authors.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

25 **These authors contributed equally to the manuscript and are joint senior authors.

27 **Word count:** ~~3538~~2802

28 **Short Title:** Environmental peanut exposure and peanut sensitization in BAMSE

For Peer Review

Abstract

Background: High household peanut consumption is associated with the development of peanut allergy, especially when peanut allergic cases are compared against atopic controls; thus environmental peanut exposure (EPE) may be a risk factor for peanut sensitization and allergy. In this study we explored the relationship between EPE and school-age peanut sensitization in a population based cohort.

Methods: Maternal bed-dust was collected postnatally and EPE was quantified using a polyclonal peanut ELISA. Peanut sensitization was assessed by peanut specific IgE to peanut extract and slgE to peanut protein component allergens molecule sensitizations (PAM) (Ara h 1, 2 or 3 ≥ 0.35 kU/L (primary peanut sensitization)). Initial nested case control analysis was performed comparing peanut sensitized cases against high-risk controls (matched for parental atopy) (n=411) using a conditional regression analysis. This was followed by whole cohort analysis (n=1878) comparing EPE against peanut slgE sensitization at ages 4 and 8 years using Generalized Estimating Equations and against primary peanut protein allergen molecule sensitization at age 8 years using a logistic regression model. Finally, a subgroup analysis was performed comparing the impact of EPE in peanut sensitized versus egg-sensitized peanut tolerant individuals using logistic regression analysis. Levels of EPE were compared between groups using the Mann-Whitney U test.

Results: ~~There was a significant association between~~ In the nested case control analysis, a higher level of -EPE around birth was associated with the presence of and peanut specific IgE sensitization at age 4 years (OR=1.41, 95% CI:1.05-1.90), and primary peanut protein allergen molecule PAM sensitization at age 8 years (OR=2.11, 95% CI:1.38-3.22) compared against high-risk controls. ~~FLG loss of function mutations, egg sensitization at age 4 years, infantile eczema and allergic rhinitis were significantly associated with peanut sensitization; however, there was no significant interaction with EPE.~~

When the whole BAMSE cohort was assessed, EPE was no longer associated with peanut sensitization; however, on subgroup analysis EPE was associated with primary peanut protein allergen molecule PAM-sensitization when compared against egg-sensitized peanut-tolerant controls

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

with an adjusted odds ratio of 1.~~4456~~ per unit EPE (95% CI:~~1.0644-1.942-12~~). There was no
significant interaction between EPE and *FLG* loss-of-function mutations, egg sensitization at age 4
years, infantile eczema or parental atopy on peanut sensitization.

Conclusions: Higher levels of environmental exposure to peanut in the first few months of life
appear to ~~EPE was associated with an~~ increase ~~the~~ probability risk of developing school age
peanut sensitization in atopic children ~~specific IgE and peanut PAM sensitization at 8 years of age~~
when comparing peanut sensitized cases against atopic controls (based on egg sensitization and
parental atopy).
(egg sensitized children or children matched for parental atopy).

Abstract word count: ~~3433~~ 254

Key words: BAMSE, egg sensitization, environmental peanut exposure, *FLG* mutation, infantile
eczema peanut sensitization

Peer Review

Funding

The research was funded/supported by Action Medical Research (S/P/4529) and by the National Institute for Health Research (NIHR) Clinical Research Facility at Guy's & St Thomas' NHS Foundation Trust and NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The BAMSE study was funded by the Swedish Research Council, the Stockholm County Council, the Swedish Research Council for Health, Working life, and Welfare the Swedish Asthma and Allergy Foundation, the Swedish Heart and Lung Foundation, and the Gillbergska Foundation.

Abbreviations

AIC: Akaike information criterion
Ara h: *Arachis hypogaea*
BAMSE: Children/'Barn' Allergy Milieu Stockholm Epidemiological project
CI: confidence intervals
EPE: environmental peanut exposure
FLG: gene encoding the protein filaggrin
GEE: Generalized Estimating Equations
ISAAC: International Study of Asthma and Allergies in Childhood
IQR: Interquartile range
~~PAM: protein allergen molecule~~
QIC: Quasi Likelihood Independence models criterion

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Peanut allergy has increased,^{1, 2} is a leading cause of anaphylaxis in food allergy³ and has a significant impact on quality of life for the child and their family.^{4, 5} Most children react on first known oral exposure to peanut; thus sensitization must be occurring earlier.^{6, 7} Understanding the way children become sensitized to peanut is therefore imperative in order to prevent this condition. Observational⁸ and animal work^{9, 10} suggests that epicutaneous peanut exposure and early onset severe eczema may play an important role in peanut sensitization.

Epicutaneous exposure may be the route that peanut levels in dust sensitize a child in early life, particularly if the skin barrier is broken through eczema or specific genetic mutations associated with skin barrier dysfunction (e.g. filaggrin (*FLG*) mutations or eczema). We have recently shown in the Manchester Asthma and Allergy Study (MAAS) and Consortium of Food Allergy Research (CoFAR) cohort that *FLG* loss-of-function mutations and eczema severity respectively can increase the impact of early EPE on peanut sensitization and allergy.^{11, 12}

A dose response relationship has also been demonstrated between household peanut consumption (used as an indirect marker for environmental peanut exposure: EPE) and the risk of developing peanut allergy in young children.¹³ ~~They~~ Fox et al. compared household peanut consumption in peanut allergic individuals against children who were at high risk of developing peanut allergy (due to the presence of egg allergy) but had not developed peanut allergy. Household peanut consumption was ten times higher in households with infants with peanut allergy versus children with egg allergy without peanut allergy but was only 3 times higher in non atopic controls, highlighting that household peanut consumption was more likely to be associated with peanut allergy in high risk children.¹³ Household peanut consumption and peanut sensitization has also been associated in other studies.¹⁴ Peanut antigen in the infant's bed-dust and play-area-dust is highly positively correlated with household peanut consumption and stimulates basophils from peanut allergic children, thus has the potential to also sensitize individuals.¹⁵

Peanut sensitization (specific IgE ≥ 0.35 kU/L) is present in up to 10% of children and protein allergen molecule (~~PAM~~) analysis of the seed storage proteins in peanut (Ara h 1, 2 and 3) has been shown to improve the specificity and sensitivity of diagnosing peanut allergy.^{16, 17} In BAMSE, children with IgE reactivity to Ara h 1, 2 or 3 at age 8 years (but not Ara h 8) reported peanut allergic symptoms in 87% of cases, whereas children with IgE reactivity exclusively to Ara h 8 reported peanut allergic symptoms in only 17% of cases which were also milder.¹⁸ Sweden has high levels of birch pollen sensitization which explains the Bet v 1 in-vitro cross-reactivity with peanut Ara h 8,¹⁸⁻²⁰ thus, in this study we differentiated between primary peanut sensitization (IgE reactivity to Ara h 1, 2 or 3) and pollen cross-reactivity (IgE reactivity to Ara h 8).

This study aimed to assess whether EPE (as defined by peanut protein levels in household dust) is a risk factor for the development of school-age peanut sensitization. The analysis was done in two steps for financial and logistical reasons; firstly among high risk children (with parental atopy matched to peanut sensitised cases), in a nested cases analysis and secondly among the whole studied population (a cohort analysis). Given previous findings we also wanted to ascertain the modifying effects of *FLG* loss-of-function mutations, infantile eczema and preceding egg sensitization.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods

The BAMSE study is an unselected Swedish population birth cohort. The design and methodology are described elsewhere.²¹ In brief 4089 unselected newborn children were recruited from 1994-1996 and have been evaluated for various health conditions over time. No intervention was performed. The BAMSE study obtained ethical approval for environmental sampling of dust.

Demographics

Serum specific IgE to peanut (ImmunoCAP system, ThermoFisher, Sweden) was measured at 4 and 8 years and children were defined as 'peanut sIgE sensitized' if peanut specific IgE was ≥ 0.35 kU/L. Peanut protein component allergens-molecules Ara h 1,2,3,8 and 9 (PAM) were assessed at 8 years (ImmunoCAP system, ThermoFisher, Sweden) in all children sensitized to peanut at age 8 years, irrespective of sensitization to birch. In addition, those children who were peanut sensitized at age 4 years but lost their sensitization at age 8 were also analyzed for these allergens. All other children with negative peanut sIgE at age 8 years were assumed to have negative component allergens to peanut. Cand children were considered to have primary be peanut PAM-protein allergen-molecule-sensitized if Ara h 1, 2 or 3 was ≥ 0.35 kU/L and not primary peanut protein allergen-molecule PAM-sensitized if Ara h 1, 2 and 3 were < 0.35 kU/L or peanut sIgE was < 0.35 kU/L at 8 years (where no sIgE peanut protein component allergens were molecules PAM available). Twenty-four (1.3%) Cchildren with positive peanut specific IgE at 8 years of age but with no available serum for peanut protein component allergen-molecule PAM analysis were excluded from this analysis. Egg sensitization was defined as egg specific IgE ≥ 0.35 kU/L at 4 years of age. Previous allergic reactions to a food including itching in the mouth, nose/eye problems, trouble breathing, vomiting or diarrhoea, eczema or nettle rash was used from parental questionnaires at age 8 years.

Parental atopy was defined as a doctor's diagnosis of asthma and prescription of asthma medication and/or a doctor's diagnosis of hay fever in combination with furred pets- and/or pollen allergy at the time of questionnaire. This definition of parental atopy was selected rather than the

same definition with inclusion of a doctor's diagnosis of eczema (excluding contact dermatitis); this was because the children of parents with atopy including eczema were less atopic (lower infantile eczema) and parental atopy including eczema was not associated with the outcome of interest (primary peanut sensitization at 8 years of age); this is probably because adult eczema is often non-atopic.

Genotyping was performed for *FLG* mutations common in Scandinavia by using TaqMan allelic discrimination assays for R501X and R2447X and matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry for 2282del4. Children with a *FLG* mutation in any of these positions were classified as having a *FLG* loss-of function mutation.

A reported history of infantile eczema was assessed by a validated eczema questionnaire with sensitivity of 92% and specificity of 100%.²² Eczema and was defined as dry skin, itchy rashes for 2 weeks or more and age specific localization (face or arms/legs extension surfaces or arms/legs flexures or wrists/ankles flexures) and/or doctor's diagnosis of eczema after 3 months and up to 1 year of age, during the first year of life. Severity of eczema was assessed from questionnaires using three different measures:

- 1) Extent of localization of eczema (up to 10 areas) at or before their one year assessment
- 2) Topical steroids used as treatment for an itchy rash in the last year at their two year assessment (not available at their one year assessment)
- 3) Persistent eczema at age 8 years (using the same definition as above).

Ethnicity was based on where the parents were born. Allergic rhinitis at 4 and 8 years was assessed using International Study of Asthma and Allergies in Childhood (ISAAC) validated questionnaires, and was defined as persistent rhinitis without a common cold the last 12 months before 4 and 8 years respectively.²³

Dust collection methodology

1
2
3
4
5
6
7 189 Dust samples were collected at a median of 2 months of age from the mother's mattress. The
8
9 190 mother's mattress was vacuumed for 2.5 minutes with a small disposable filter bag (Allergy Control
10
11 191 Products Inc. Ridgefield CT, USA) inserted in the front hose of the vacuum. The dust containing
12 192 filter bags were sealed in plastic bags and stored at -20°C. Dust samples were sieved and fine dust
13
14 193 was weighed and extracted in proportional volumes of extraction solution as previously described.²⁴
15
16 194 Peanut protein in dust was determined using the Veratox polyclonal ELISA against whole peanut
17
18 195 protein (Neogen Corporation, Lansing, MI, USA). The lower limit of quantitation (LLQ) of the assay
19 196 was defined as 100ng/ml and samples below this value were defined as 50ng/ml (LLQ/2).²⁵ Results
20
21 197 were converted from ng/ml into µg peanut protein/gram dust. Due to batch to batch variability of the
22
23 198 Veratox ELISA results were batch corrected prior to being entered into the final statistical analysis.

24
25
26 200 **Statistical analysis**

27
28 201 Data was entered into an SPSS (SPSS 19.0; SPSS Inc, Chicago, IL, USA) and STATA spreadsheet
29
30 202 (Timberlake Consultants Ltd London, UK) for the purpose of analysis. Peanut protein levels in dust
31 203 (µg/gram) underwent natural log transformation. Initial nested case control analysis was performed
32
33 204 with peanut sIgE sensitized cases at 4 years of age matched for gender and parental atopy with a
34
35 205 2:1 control (n=274) to case (n=137) matching. Children with primary peanut protein allergen
36
37 206 molecule PAM sensitization defined by Ara h 1, 2 or 3 ≥0.35kU/L at 8 years of age were ~~also~~
38 207 matched against controls at age 8 years with the same matched sex for gender and level of parental
39
40 208 atopy with a 2:1 ratio of controls (n=130) to cases (n=65). Given that these controls were matched
41
42 209 for the higher levels of parental atopy in the primary peanut sensitized cases these controls were
43
44 210 deemed to be high-risk as the primary peanut sensitized cases had higher levels of parental atopy
45 211 than the population overall (46.7% vs. 32.6%). Conditional logistic regression (incorporating
46
47 212 matching) was performed for the case control analysis using robust standard error for peanut sIgE
48
49 213 sensitization at 4 years and primary peanut sensitization at age 8 years.

50
51 214 Subsequently analysis was performed for the relationship between early EPE and peanut
52
53 215 sensitization in all children from the BAMSE cohort with available postnatal maternal bed-dust and
54
55
56
57
58
59
60

1
2
3
4
5
6
7 216 | *FLG* genotyping (n=1878). Logistic regression analysis was performed for primary peanut protein
8
9 217 | allergen molecule PAM sensitization at 8 years of age. Factors associated with peanut sIgE
10
11 218 | sensitization were assessed using Generalized Estimating Equations (GEE) with an exchangeable
12
13 219 | working correlation matrix to account for repeated measures within individuals at 4 and 8 years.
14
15 220 | Univariate followed by multivariate regression analysis was performed including EPE, ~~*FLG* loss-of-~~
16
17 221 | ~~function mutations, infantile eczema and egg sensitization at 4 years of age~~ plus other covariates
18
19 222 | significantly associated with peanut sensitization ($P \leq .05$) which also improved the quality of fit of the
20
21 223 | multivariate model using the Akaike information criterion (AIC) for logistic regression and the Quasi
22
23 224 | Likelihood Independence models criterion (QIC) for GEE analyses.
24
25 225 | Where the *FLG* mutation covariate was entered into the statistical model, participants with missing
26
27 226 | ethnicity data (35/1878=1.9%) and non-caucasians (165/1842=8.8%) were excluded as distinct *FLG*
28
29 227 | loss-of-function mutations are present in different populations and the *FLG* loss-of-function
30
31 228 | mutations assessed in this study have only been associated with eczema in Caucasian European
32
33 229 | populations ^{26, 27} Peanut levels in dust ($\mu\text{g/g}$) were compared between groups using the Mann-
34
35 230 | Whitney U test. ~~Proportions between groups (e.g. infantile eczema and *FLG* mutations) were~~
36
37 231 | ~~compared using Pearson chi squared.~~ Statistical significance was assessed at $P < .05$.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

Details of demographics and clinical characteristics included on this study are described in Table E1. Median peanut protein [IQR] in dust was 4.07µg/gram [1.58, 11.86]. Peanut extract sIgE sensitization was 6.6% at 4 years (n=103/1572) and 8.6% at 8 years (n=161/1876). Primary peanut protein allergen molecule PAM sensitization at 8 years was 4.1% (n=75/1854), of which 74/75 (99%) had Ara h 2 ≥0.35kU/l. We first performed a nested case control analysis, and based on positive findings for this subsequently proceeded to then analyse the whole BAMSE cohort.

Nested case control analysis for peanut sIgE and primary peanut protein allergen molecule PAM sensitization

We compared peanut sensitized children against children without peanut sensitization matched for gender and parental atopy as described in the statistical methods; EPE was a risk factor for both peanut extract sIgE sensitization at 4 years and primary peanut protein allergen molecule PAM sensitization at 8 years with a 23% and 29% increased probability of developing risk of peanut sensitization per natural log (ln) unit increase in EPE respectively (Table I). In children who were peanut extract sIgE sensitized but not peanut protein allergen molecule PAM sensitized to peanut protein component allergens Ara h 1, 2 and/or 3, there was only borderline significance towards an association between EPE and peanut sensitization (OR=1.20, 95% CI: 0.97-1.48).

Differential relationship between EPE and primary peanut protein allergen molecule PAM sensitization and non-clinically significant peanut sensitization is displayed in Figure 1. Median peanut protein in dust was higher in peanut extract sIgE sensitized children (3.39 µg/g, IQR 1.41-11.01, n=137) than non-peanut extract sIgE sensitized controls (2.28µg/g, IQR 0.88-5.14, n=274) ($P<.01$); and higher in primary peanut protein allergen molecule PAM sensitized children (4.64µg/g, IQR 1.58-12.77, n=65) than in control children that were not sensitized to Ara h 1,2 or 3 non-peanut protein allergen molecule PAM sensitized controls (2.24µg/g, IQR 0.88-4.74, n=130) ($P<.01$).

On multivariate conditional logistic regression analysis, EPE was significantly associated with peanut specific IgE and primary peanut protein allergen molecule PAM sensitization with a 1.41- and

2.1-fold increased probability of developing peanut sensitization risk per unit increase EPE respectively (Table II).

Infantile eczema and egg sensitization were both significantly associated with sensitization to peanut extract slgE and protein-allergen-moleculePAM sensitization to peanut protein component allergens Ara h 1, 2 and/or 3 (Table II). *FLG* loss-of function mutations increased the risk of probability of developing peanut specific IgE sensitization 3.78-fold and primary peanut protein-allergen-moleculePAM sensitization 7.33-fold. Allergic rhinitis at age 4 and 8 years was associated with both the probability of developing peanut specific IgE sensitization at age 4 years and primary peanut protein-allergen-moleculePAM sensitization at age 8 years in the multivariate analysis. The number of biological siblings, duration of exclusive and total breastfeeding and maternal age at baseline were not risk-factors associated with for peanut sensitization. There was no significant interaction between EPE and either infantile eczema, egg sensitization or *FLG* loss-of-function mutations on primary peanut protein-allergen-moleculePAM sensitization (data not shown).

Whole cohort analysis for peanut extract slgE sensitization and primary peanut sensitizationprotein-allergen-moleculePAM sensitization

In a second step following positive findings obtained on case control analysis, we assessed analysis was performed for the relationship between early EPE and peanut sensitization in all children from the BAMSE cohort with available postnatal maternal bed-dust and *FLG* genotyping (n=1878). On both univariate (Table III) and multivariate analysis (Table IV) infantile eczema, egg sensitization at age 4 years, tree nut and soya allergy at age 8 years, FLG loss-of function mutation and allergic rhinitis at age 8 years were associated with the probability of peanut extract-slge sensitization at age 4 and 8 years. For primary peanut protein-allergen-moleculePAM sensitization at age 8 significant associations were also seen on univariate (Table III) and multivariate analysis (Table IV) for infantile eczema, egg sensitization, tree nut and soya allergy at age 8 years and allergic rhinitis at age 8 years. Although measures of eczema severity several other food allergies at age 8 years

1
2
3
4
5
6
7 were significantly association with peanut sensitization on univariate analysis, these variables were
8
9 no longer significantly associated on multivariate analysis. However, EPE was not longer associated
10
11 with peanut slgE sensitization or primary peanut protein allergen molecule sensitization. There was
12 no interaction between EPE and *FLG* mutations, infantile eczema, egg sensitization, allergic
13 reaction to tree nut or soya by age 8 years, or parental atopy on peanut sensitization.
14
15
16
17
18
19 **Subgroup analysis of primary peanut protein allergen molecule ~~PAM~~ sensitization against egg**
20 **sensitized non peanut allergic individuals**
21
22
23 On subgroup analysis we compared primary peanut protein allergen molecule ~~PAM~~ sensitized
24 children (n=75) against children who were sensitized to egg (slgE≥0.35kU/L at age 4 years) but did
25 not go on to ~~develop~~ have primary peanut protein allergen molecule ~~PAM~~ sensitization at age 8
26 years (n=59). EPE increased the probability was a risk factor for of primary peanut protein allergen
27 molecule ~~PAM~~ sensitization on both univariate (OR=1.33 95% CI:1.01-1.74, *P*<.05, n=134) (Table V)
28 and multivariate analysis (OR=1.4456, 95% CI:1.0644-1.942, *P*<.018, n=1332, AIC: 167334)
29 adjusting for allergic rhinitis at age 8 years and infantile eczema and allergic reaction to soya by
30 age 8 years. Peanut levels in household dust were also significantly higher in primary peanut
31 protein allergen molecule ~~PAM~~ sensitized children (median 4.79µg/g, IQR 1.63-12.00) versus egg
32 sensitized, non-primary peanut protein allergen molecule ~~PAM~~ sensitized children (median 2.35µg/g,
33 IQR 1.23-6.15) (*P*=.03).
34
35
36
37
38
39
40
41
42
43 We assessed the impact of EPE on peanut sensitization when using other high-risk groups of
44 children who were not did not become peanut sensitized at age 8 years (*FLG* mutations, infantile
45 eczema, soya allergy and, parental atopy) and there was no significant association.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

In the prospective birth cohort BAMSE, there was an exposure-response relationship between EPE (quantified using peanut protein levels from maternal mattress-dust postnatally) and primary peanut protein-allergen-moleculePAM-sensitization (Ara h 1, 2 or 3 ≥ 0.35 kU/L) among high risk children (in a nested cases analysis). When all children in the whole studied population were assessed, there was no association between EPE and peanut sensitization; however, on subgroup analysis there was an exposure-response relationship between EPE and primary peanut protein-allergen-moleculePAM-sensitization when compared against high risk egg sensitized children.

~~This supports the findings by Fox et al. also showed that where~~ household peanut consumption during the first year of life (as an indirect marker of EPE) was higher in peanut allergic cases than in egg allergic controls.¹³ ~~In the nested cases analysis the exposure-response relationship between EPE and PS (when compared against atopic controls)~~ was stronger between EPE and primary peanut protein-allergen-moleculeCRD-sensitization (Ara h 1,2 or 3 ≥ 0.35 kU/L) than between EPE and non-clinically relevant peanut sensitization (peanut sIgE ≥ 0.35 kU/L but negative results for Ara h 1,2 or 3 < 0.35 kU/L) (Figure 1). This supports the concept that EPE increases the probability of developing clinically relevant peanut sensitization which is more likely to develop into peanut allergy rather than non-specific peanut sensitization.

~~The association between household peanut consumption and peanut sensitization was also found in a study by Garcia-Boyano et al.¹⁴ and supports the concept that EPE increases the risk of clinically relevant peanut sensitization.~~

In other cohorts we have shown a synergistic effect between EPE and markers of an impaired skin barrier (infantile eczema and *FLG* loss-of-function mutations) on peanut sensitization and allergy.¹¹

¹² Although in BAMSE we did not find significant interactions between EPE and *FLG* mutations or infantile eczema on peanut sensitization, we did show on subgroup analysis that early EPE has more impact on the probability of developing peanut sensitization when compared against high risk

1
2
3
4
5
6
7 336 children (defined by parental atopy in the nested cases analysis and egg sensitization in the whole
8 cohort analysis) in children with certain risk factors for the development of peanut sensitization
9 337 (such as parental atopy or egg sensitization) than in children without these risk factors. The BAMSE
10 338 cohort is relatively non-atopic, being from the general population in Sweden, which may have
11 339 contributed to lower strength of associations between EPE and atopic markers. The median level of
12 340 peanut protein in maternal bed-dust dust in the BAMSE cohort was 4.07µg/gram [IQR 1.58, 11.86],
13 341 similar to that found in another the UK study by our group (median 4.19 IQR 0.54-24.89).²⁴ The
14 342 level of peanut in dust was higher in a US study that measured peanut from the living room floor
15 343 (median 39.1ug/g IQR 0.4-1.33).⁽¹⁰⁾ It would, however, be expected that peanut levels would be
16 344 higher in America due to higher levels of peanut consumption.
17
18
19
20
21
22
23 345
24
25 346
26
27 347 Infantile eczema was one of the most important risk factors for peanut sensitization in BAMSE; this
28
29 348 association has been cited in numerous studies.^{8, 28} ~~FLG loss of function mutations were less~~
30 349 ~~important than infantile eczema in predicting the development of peanut sensitization, and FLG~~
31 350 ~~mutations became more important if infantile eczema was not included in the regression model.~~
32
33
34 351 ~~Previous studies have found that children that carry a FLG mutation have an increased risk of~~
35 352 ~~peanut allergy even after adjusting for eczema.²⁹ In this study eczema seemed to be the overriding~~
36 353 ~~factor for peanut sensitization; however, it should be noted that FLG mutations were quite low in~~
37 354 ~~BAMSE (7.14%) in comparison with other population based cohorts.^{26, 29} Measures of eczema~~
38 355 ~~severity (extent of localisation, topical steroid use and persistent eczema) were associated with~~
39 356 ~~peanut sensitization on univariate analysis but were no longer associated on multivariate analysis.~~
40 357 Eczema severity has previous been shown to be an independent risk factor for food sensitization in
41 358 the EAT (Enquiring About Tolerance) study.³⁰ The EAT study used the SCORAD eczema severity
42 359 scoring system; however, this could not be performed in the BAMSE study as the evaluations at 1,
43 360 2, 4 and 8 years were based on parental questionnaires.
44
45
46
47
48
49
50
51 361
52
53
54
55
56
57
58
59
60

Egg sensitization was highly associated with peanut sensitization; which has previously been shown in numerous cohort studies;^{11, 12, 31} it may be that egg sensitization shows a predisposition to mount allergic antibodies to other allergens as egg allergy is highly associated with the development of other food allergies, asthma and aeroallergen sensitization.^{32, 33} Observational studies have shown that in children with severe, early onset eczema, up to 50% are sensitized to egg;²⁸ thus egg sensitization may be an additional marker of eczema severity. FLG loss-of-function mutations were less important than infantile eczema in predicting the development of peanut sensitization, and FLG mutations became more important if infantile eczema was not included in the regression model. Previous studies have found that children that carry a FLG mutation have an increased risk of peanut allergy even after adjusting for eczema.²⁹ In this study eczema seemed to be the overriding factor for peanut sensitization; however, it should be noted that FLG mutations were quite low in BAMSE (7.14%) in comparison with other population-based cohorts.^{26, 29, 34} Tree nut and/or soya allergy by age 8 was also associated with primary peanut sensitization at age 8 years; co-existent peanut and tree-nut allergy has been shown in numerous studies,^{35, 36} whereas co-existent soya and peanut allergy is reportedly low.³⁷

Strength of the present study includes the population based design and relatively high number of study participants. Limitations of this study included the lack of diagnostic food challenges to determine peanut allergy as the BAMSE study was not originally designed to evaluate peanut allergic outcomes; however, primary peanut ~~protein allergen molecule~~ PAM sensitization has been shown to be a much more accurate predictor of clinically confirmed peanut allergy than peanut specific IgE.^{38, 39} Certain potential confounders were not available such as parental peanut allergy or other parental food allergies, maternal peanut consumption during pregnancy and breast-feeding and infant peanut consumption. Therefore we are unable to assess whether infant peanut consumption could have protected the children against environmental exposure to peanut sensitization as has been shown in previous studies;^{13, 35} however, when BAMSE was recruiting participants in 1996 the number of infants eating peanut was very low. Caucasian ethnicity was defined based on place of parental birth rather than self-reported ethnicity; however, when the

1
2
3
4
5
6
7 390 ~~BAMSE study was recruiting participants 1994-1996, most parents born in Sweden or Northern~~
8
9 391 ~~Europe would have been of Caucasian descent. as being born in Sweden as between 1994-1996~~
10
11 392 ~~(when the BAMSE cohort commenced), most participants born in Sweden would have been of~~
12
13 393 ~~Northern European descent. In addition participants from Finland, Greece or Eastern Europe who~~
14 394 ~~were not born in Sweden were also defined as Caucasian.~~⁴⁰ Findings on case control analysis could
15
16 395 not be replicated on whole cohort analysis, therefore these findings need to be confirmed in other
17
18 396 population based cohorts. ~~Strength of the present study includes the population based design and~~
19 397 ~~relatively high number of study participants.~~
20
21
22 398

23 399 **Conclusion**

24
25 400 In summary, although EPE did not increase the risk of peanut sensitization in children who did not
26
27 401 already have atopic risk factors, the findings from the BAMSE cohort support the hypothesis that in
28
29 402 specific high risk groups, peanut levels in dust around the time of birth may pose a risk for later
30
31 403 peanut sensitization. Further prospective studies are needed to confirm these findings in other
32 404 populations.
33
34 405

35 406 **Acknowledgement**

36
37 407 We wish to thanks Dr Alick Stephens for his assistance in the BAMSE dust analysis. The authors
38 408 thank all children and their parents in the BAMSE cohort
39 409
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

- (1)— Venter C, Hasan AS, Grundy J, Pereira B, Bernie CC, Voigt K et al. Time trends in the prevalence of peanut allergy: three cohorts of children from the same geographical location in the UK. *Allergy* 2010; 65(1):103-8.
- (2)— Sicherer SH, Munoz-Furlong A, Godbold JH, Sampson HA. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. *J Allergy Clin Immunol* 2010; 125(6):1322-6.
- (3)— Bock SA, Munoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. *J Allergy Clin Immunol* 2007; 119(4):1016-8.
- (4)— Avery NJ, King RM, Knight S, Hourihane JO'B. Assessment of quality of life in children with peanut allergy. *Pediatric Allergy & Immunology* 2003;(5):378-82.
- (5)— King RM, Knibb RC, Hourihane JO. Impact of peanut allergy on quality of life, stress and anxiety in the family. *Allergy* 2009; 64(3):461-8.
- (6)— Hourihane JO'B, Kilburn SA, Dean P, Warner JO. Clinical characteristics of peanut allergy. *Clin Exp Allergy* 1997; 27(6):634-9.
- (7)— Monti G, Muratore MC, Peltran A, Bonfante G, Silvestro L, Oggero R et al. High incidence of adverse reactions to egg challenge on first known exposure in young atopic dermatitis children: predictive value of skin prick test and radioallergen sorbent test to egg proteins. *Clin Exp Allergy* 2002; 32(10):1515-9.
- (8)— Lack G, Fox D, Northstone K, Golding J, Avon Longitudinal Study of Parents and Children Study Team. Factors associated with the development of peanut allergy in childhood. *N Engl J Med* 2003; 348(11):977-85.
- (9)— Strid J, Hourihane J, Kimber I, Callard R, Strobel S. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. *Eur J Immunol* 2004; 34(8):2100-9.
- (10)— Brough HA, Liu AH, Sicherer S, Makinson K, Douiri A, Brown SJ et al. Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy. *J Allergy Clin Immunol* 2015; 135(1):164-70.
- (11)— Brough H.A., Simpson A., Makinson K., Sara B., Douiri A., Belgrave D. et al. Peanut allergy: Impact of environmental peanut exposure in children with filaggrin loss-of-function mutations. *J Allergy Clin Immunol* 2014; 134:867-75.
- (12)— Fox AT, Sasieni P, Du Toit G, Syed H, Lack G. Household peanut consumption as a risk factor for the development of peanut allergy. *J Allergy Clin Immunol* 2009; 123(2):417-23.
- (13)— Garcia-Boyano M, Pedrosa M, Quirce S, Boyano-Martinez T. Household almond and peanut consumption is related to the development of sensitization in young children. *J Allergy Clin Immunol* 2016; 137(4):1248-51.
- (14)— Brough HA, Santos A, Makinson K, Penagos M, Stephens AC, Fox AT et al. Peanut protein in household dust is related to household peanut consumption and is biologically active. *J Allergy Clin Immunol* 2013; 132(3):630-8.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

~~Quantification of specific IgE to whole peanut extract and peanut components in prediction of peanut allergy. J Allergy Clin Immunol 2011; 127(3):684-5.~~

~~-(16) Dang TD, Tang M, Choo S, Licciardi PV, Koplin JJ, Martin PE et al. Increasing the accuracy of peanut allergy diagnosis by using Ara h 2. J Allergy Clin Immunol 2012; 129(4):1056-63.~~

~~-(17) Asarnoj A, Ostblom E, Kull I, Lilja G, Pershagen G, Hedlin G et al. Sensitization to inhalant allergens between 4 and 8 years of age is a dynamic process: Results from the BAMSE birth cohort. Clin Exp Allergy 2008; (9):1507-13.~~

~~-(18) Asarnoj A, Ostblom E, Ahlstedt S, Hedlin G, Lilja G, van HM et al. Reported symptoms to peanut between 4 and 8 years among children sensitized to peanut and birch pollen—results from the BAMSE birth cohort. Allergy 2010; 65(2):213-9.~~

~~-(19) Wickman M, Kull I, Pershagen G, Nordvall SL. The BAMSE project: presentation of a prospective longitudinal birth cohort study. Pediatr Allergy Immunol 2002; 13:Suppl 3.~~

~~-(20) Strachan D, Sibbald B, Weiland S, Ait Khaled N, Anabwani G, Anderson HR et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 1997; 8(4):161-76.~~

~~-(21) Brough HA, Makinson K, Penagos M, Maleki SJ, Cheng H, Stephens AC et al. Distribution of peanut protein in the home environment. J Allergy Clin Immunol 2013; 132(3):623-9.~~

~~-(22) Hornung RW, Reed LD. Estimation of average concentration in the presence of nondetectable values. App Occup Environ Hyg 1990; 5:46-51.~~

~~-(23) Baurecht H, Irvine AD, Novak N, Illig T, Buhler B, Ring J et al. Toward a major risk factor for atopic eczema: Meta-analysis of filaggrin polymorphism data. J Allergy Clin Immunol 2007; 120(6):1406-12.~~

~~-(24) Weidinger S, O'Sullivan M, Illig T, Baurecht H, Depner M, Rodriguez E et al. Filaggrin mutations, atopic eczema, hay fever, and asthma in children. J Allergy Clin Immunol 2008; 121(5):1203-9.~~

~~-(25) Hill DJ, Hosking CS, Oranje AP, Bauchau V, Naspitz CK, Simons FER et al. Confirmation of the association between high levels of immunoglobulin E food sensitization and eczema in infancy: An international study. Clin Exp Allergy 2008; 38(1):161-8.~~

~~-(26) Brown SJ, Asai Y, Cordell HJ, Campbell LE, Zhao Y, Liao H et al. Loss of function variants in the filaggrin gene are a significant risk factor for peanut allergy. J Allergy Clin Immunol 2011; 127(3):661-7.~~

~~-(27) Du Toit G, Roberts G, Sayre P, Plaut M. Identifying infants at high risk of peanut allergy—The LEAP Screening Study. J Allergy Clin Immunol 2013; 131(1):135-43.~~

~~-(28) Tariq SM, Matthews SM, Hakim EA, Arshad SH. Egg allergy in infancy predicts respiratory allergic disease by 4 years of age. Pediatric Allergy & Immunology 2000; 11(3):162-7.~~

~~-(29) Gaffin JM, Sheehan WJ, Morrill J, Cinar M, Borrás-Coughlin IM, Sawicki GS et al. Tree nut allergy, egg allergy, and asthma in children. Clin Pediatr 2011; 50(2):133-9.~~

~~—(30) Nicolaou N, Poorafshar M, Murray C, Simpson A, Winell H, Kerry G et al. Allergy or tolerance in children sensitized to peanut: prevalence and differentiation using component-resolved diagnostics. J Allergy Clin Immunol 2010; 125(1):191-7.~~

~~—(31) Beyer K, Grabenhenrich L, Hartl M, Beder A, Kalb B, Ziegert M et al. Predictive values of component specific IgE for the outcome of peanut and hazelnut food challenges in children. Allergy 2015; 70(1):90-8.~~

~~—(32) Du Toit G, Katz Y, Sasieni P, Mesher D, Maleki SJ, Fisher HR et al. Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy. J Allergy Clin Immunol 2008; 122(5):984-91.~~

~~—(33) Besharat PM, Bergstrom A, Bottai M, Kull I, Wickman M, Hakansson N et al. Effect of parental migration background on childhood nutrition, physical activity, and body mass index. J Obesity 2014; 2014:406529.~~

Table E1: Demographics of whole studied BAMSE population with available dust and *FLG* genotyping (n=1878)

	Number of cases	No. data points	Percentage <u>of cases / no. of available data points</u>
Peanut specific IgE ≥ 0.35kU/L at 4 years	103	1572	6.55%
Peanut specific IgE ≥ 0.35kU/L at 8 years	161	1876	8.58%
Ara h 1, 2 or 3 ≥0.35kU/L at 8 years vs. Ara h 1, 2 or 3 <0.35kU/L or peanut sIgE <0.35kU/L (excluding peanut sIgE ≥0.35kU/L with no components <u>or missing data</u>) at 8 yrs	75	1854	4.05%
History of infantile atopic dermatitis	313	1840	17.01%
<u>Topical steroid use between age 1-2 years</u>	<u>534</u>	<u>1842</u>	<u>29.0%</u>
<u>Higher extent of localisation of eczema (>5 areas vs. <5 areas or no eczema)</u>	<u>49</u>	<u>1841</u>	<u>2.7%</u>
<u>Persistent eczema at age 8 years</u>	<u>321</u>	<u>1828</u>	<u>17.6%</u>
At least one <i>FLG</i> mutation (R501X, 2282del or R2447x)	134	1878	7.14%
Allergic rhinitis (ISAAC definition) (age 4 years)	215	1828	11.76%
Allergic rhinitis (ISAAC definition) (age 8 years)	288	1865	15.44%
Egg sIgE ≥ 0.35IU/ml at 4 years of age	82	1575	5.21%
<u>Reported allergic reaction to any food 8 years</u>	<u>349</u>	<u>1869</u>	<u>18.7%</u>
<u>Reported allergic reaction to peanut by 8 years</u>	<u>120</u>	<u>1869</u>	<u>6.4%</u>
<u>Reported allergic reaction to milk by 8 years</u>	<u>53</u>	<u>1869</u>	<u>2.8%</u>
<u>Reported allergic reaction to egg by 8 years</u>	<u>36</u>	<u>1869</u>	<u>1.9%</u>
<u>Reported allergic reaction to fish by 8 years</u>	<u>12</u>	<u>1869</u>	<u>0.6%</u>
<u>Reported allergic reaction to shellfish 8 years</u>	<u>17</u>	<u>1869</u>	<u>0.9%</u>
<u>Reported allergic reaction to wheat by 8 years</u>	<u>9</u>	<u>1869</u>	<u>0.5%</u>
<u>Reported allergic reaction to soya by 8 years</u>	<u>21</u>	<u>1869</u>	<u>1.1%</u>
<u>Reported allergic reaction to apple by 8 years</u>	<u>83</u>	<u>1869</u>	<u>4.4%</u>
<u>Reported allergic reaction to peach by 8 years</u>	<u>44</u>	<u>1869</u>	<u>2.4%</u>
<u>Reported allergic reaction to kiwi by 8 years</u>	<u>92</u>	<u>1869</u>	<u>4.9%</u>
<u>Reported allergic reaction to avocado 8 years</u>	<u>14</u>	<u>1869</u>	<u>0.7%</u>

Reported allergic reaction to banana by 8 years	17	1869	0.9%
Reported allergic reaction to carrot by 8 years	53	1869	2.8%
Reported allergic reaction to tree nuts 8 years	105	1869	5.6%
Male gender	973	1871	52.00%
Caucasian ethnicity	1677	1842	91.04%
Biological siblings	1695	1870	90.64%
Parental atopy – (asthma/AR/ eczemaAD)	838	1858	45.10%
Parental atopy – (asthma/AR)	605	1856	32.60%
Maternal age (mean, SD)	30.9 (SD 4.49)	1871	N/A
Peanut protein in maternal bed-dust (µg/g): median [IQR]	4.07 [1.58-11.86]	1878	N/A
Exclusive breast-feeding duration (months): mean (SD)	5.19 (2.43)	1838	N/A
Total breast-feeding duration (months): mean (SD)	8.73 (3.31)	1825	N/A

Peer Review

Table I: Univariate conditional logistic regression incorporating matching for peanut sensitized cases versus non-sensitized controls matched for gender and parental atopy. Peanut sIgE sensitization (≥ 0.35 kU/L) at age 4 years and primary peanut protein allergen molecule PAM sensitization (Ara h 1, 2 or 3 ≥ 0.35 kU/L) at age 8 years.

	Peanut sIgE sensitized at age 4 years (n=411)			Peanut PAM sensitized at age 8 years (n=195)		
	OR	95% CI	P value	OR	95% CI	P-value
EPE (μ g/gram In transformed)	1.23	1.06-1.43	<.01	1.29	1.04-1.61	.02
No. of biological siblings	1.38	0.63-3.03	.42	2.50	0.77-8.16	.13
≥ 1 FLG loss-of-function mutation (excluding non-caucasians)	2.67	1.18-6.04	.02	3.00	0.84-10.75	.09
History of infantile eczema	7.35	4.20-12.83	<.001	6.39	2.95-13.83	<.001
Egg sIgE sensitization: 4 years	18.91	7.50-47.66	<.001	12.85	3.78-43.67	<.001
*Allergic rhinitis: 4 years (ISAAC)	3.44	1.90-6.23	<.001	2.53	1.04-6.18	.04
*Allergic rhinitis: 8 years (ISAAC)	11.44	5.68-23.07	<.001	12.97	4.54-37.05	<.001
Exclusively breastfed (months)	0.95	0.88-1.03	.22	0.98	0.87-1.11	.77
Breastfed (excl/partial) (months)	0.99	0.93-1.05	.74	1.01	0.93-1.11	.76
Maternal age at baseline (in years)	0.99	0.94-1.04	.65	1.05	0.99-1.12	.12

*Allergic rhinitis was included to assess whether false positive results for peanut sensitization were being found due to cross-reactivity with grass or tree pollens.

Table II: Multivariate conditional logistic regression incorporating matching for peanut sensitized cases versus non-sensitized controls matched for gender and parental atopy. Peanut sIgE sensitization (≥ 0.35 kU/L) at age 4 years and primary peanut protein-allergen-molecule PAM sensitization (Ara h 1, 2 or 3 ≥ 0.35 kU/L) at age 8 years. Non-caucasians were excluded due to inclusion of *FLG* mutations as a covariate.

	Peanut sIgE sensitized at age 4 years (excluding non-caucasians) (n=237) *AIC: 90.78			<u>Primary p</u> Peanut <u>PAM</u> sensitization at age 8 years (excluding non-caucasians) (n=143) *AIC: 49.19		
	OR	95% CI	P Value	OR	95% CI	P Value
EPE (μ g/gram In transformed)	1.41	1.05-1.90	.02	2.11	1.38-3.22	.001
≥ 1 <i>FLG</i> loss-of-function mutation	3.78	0.93-15.36	.06	7.33	1.21-44.21	.03
History of infantile eczema	2.53	0.98-6.51	.05	3.93	1.03-15.00	.05
Egg sIgE sensitization: 4 years	28.00	5.24-149.39	<.001	39.9	1.47-1081.68	.03
**Allergic rhinitis: 8 years (ISAAC)	12.57	4.164-37.98	<.001	28.93	3.77-221.61	<.001

*Smaller AIC is better. **Allergic rhinitis at age 8 years was selected as it improved the fit of the model (AIC better than allergic rhinitis at age 4 years).

Table III: Univariate analysis of peanut specific IgE sensitization aged 4 and 8 years using GEE to account for repeated measures within individuals at 4 and 8 years and logistic regression for primary peanut PAM sensitization at age 8 years in the whole BAMSE cohort (n=1878).

	GEE for peanut sIgE			Univariate primary peanut		
	Univariate peanut sIgE sensitisation at 4 +8 years			sensitisation at age 8 years		
	OR	95% CI	P Value	OR	95% CI	P Value
EPE (µg/gram ln transformed)	0.95	0.86-1.06	0.39	1.01	0.86-1.19	.89
Gender	1.14	0.83-1.56	0.43	1.41	0.88-2.26	.15
Full older siblings	1.08	0.63-1.85	0.77	0.86	0.40-1.81	0.68
≥1 FLG loss-of-function mutations	1.84	1.10-3.05	0.0219	1.84	0.89-3.77	0.10
Questionnaire based history of infantile eczema	6.49	4.66-9.02	<.001	7.94	4.91-12.83	<.001
<u>Localisation of infantile eczema (continuous 1-10 areas/per unit)</u>	<u>1.48</u>	<u>1.37-1.59</u>	<u><.001</u>	<u>1.53</u>	<u>1.40-1.68</u>	<u><.001</u>
<u>Localisation of infantile eczema (<5 areas vs. 5+ areas)</u>	<u>7.69</u>	<u>4.26-13.55</u>	<u><.001</u>	<u>10.4</u>	<u>5.24-20.65</u>	<u><.001</u>
<u>Application of topical steroids for itchy rash (1-2 yrs)</u>	<u>3.24</u>	<u>2.35-4.46</u>	<u><.001</u>	<u>3.95</u>	<u>2.46-6.34</u>	<u><.001</u>
<u>Persistent eczema at age 8 years</u>	<u>3.87</u>	<u>2.76-5.44</u>	<u><.001</u>	<u>2.85</u>	<u>1.69-4.81</u>	<u><.001</u>
Egg sIgE sensitisation at 4 years	13.58	8.55-21.58	<.001	11.04	6.13-19.90	<.001
<u>Allergic reaction to milk by 8 years</u>	<u>5.68</u>	<u>3.12-10.34</u>	<u><.001</u>	<u>4.24</u>	<u>1.84-9.77</u>	<u>0.001</u>
<u>Allergic reaction to egg by 8 years</u>	<u>26.81</u>	<u>13.98-51.4</u>	<u><.001</u>	<u>16.67</u>	<u>7.81-35.59</u>	<u><.001</u>
<u>Allergic reaction to fish by 8 years</u>	<u>17.25</u>	<u>5.41-54.96</u>	<u><.001</u>	<u>9.18</u>	<u>2.39-35.32</u>	<u>0.001</u>
<u>Allergic reaction to shellfish 8 years</u>	<u>15.59</u>	<u>6.07-40.02</u>	<u><.001</u>	<u>3.70</u>	<u>0.82-16.71</u>	<u>0.09</u>
<u>Allergic reaction to wheat by 8 years</u>	<u>9.55</u>	<u>2.53-36.02</u>	<u>0.001</u>	<u>8.06</u>	<u>1.60-40.59</u>	<u>0.01</u>
<u>Allergic reaction to soya by 8 years</u>	<u>48.75</u>	<u>17.61-134.97</u>	<u><.001</u>	<u>41.95</u>	<u>16.56-106.24</u>	<u><.001</u>

Formatted: Swedish (Sweden)

Allergic reaction to apple by 8 years	12.54	8.16-19.27	<.001	5.93	3.15-11.13	<.001
Allergic reaction to peach by 8 years	14.37	8.15-25.34	<.001	6.49	2.88-14.61	<.001
Allergic reaction to kiwi by 8 years	5.95	3.80-9.31	<.001	4.25	2.20-8.20	<.001
Allergic reaction to avocado 8 years	12.27	4.61-32.66	<.001	4.38	0.95-20.13	0.06
Allergic reaction to banana 8 years	12.19	5.07-29.30	<.001	3.44	0.77-15.40	0.11
Allergic reaction to carrot by 8 years	17.84	10.6-30.05	<.001	7.83	3.83-16.03	<.001
Allergic reaction to tree nuts 8 years	21.93	14.45-33.28	<.001	10.29	12.08-34.05	<.001
Allergic rhinitis aged 4 years	2.82	1.92-4.13	<.001	2.16	1.22-3.83	0.008
Allergic rhinitis aged 8 years	8.05	5.78-11.22	<.001	5.87	3.66-9.42	<.001
Parental atopy (asthma and/or AR)	1.77	1.28-2.44	<.001	1.77	1.10-2.83	0.018
Parental atopy (asthma, AR,eczema)	1.44	1.05-1.98	0.02	1.50	0.95-2.39	0.09
Non-caucasian ethnicity	1.58	0.97-2.57	0.07	1.09	0.49-2.43	0.79
Exclusively breastfed in months	0.98	0.94-1.06	0.92	0.97	0.88-1.06	0.49
Breastfed (exclusive/partial) in mo	0.99	0.94-1.03	0.57	0.97	0.91-1.04	0.43
Maternal age at baseline (in years)	1.02	0.98-1.05	0.44	1.02	0.97-1.07	0.53

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table IV: Multivariate analysis of peanut specific IgE sensitization aged 4 and 8 years using generalised estimating equations (GEE) to account for repeated measures within individuals at 4 and 8 years and logistic regression analysis for primary peanut ~~PAM~~ sensitization at age 8 years in the BAMSE cohort. ~~-excluding non-caucasians-~~ Goodness of fit assessed by QIC and AIC.

	Multivariate peanut sIgE sensitization (excluding non-caucasians) (n=136788) QIC:935.44094			Multivariate <u>primary</u> peanut PAM -sensitization (excluding non-caucasians) (n=1521375) AIC:386767		
	OR	95% CI	P Value	OR	95% CI	P Value
EPE (µg/gram ln transformed)	0.948	0.8084-1.113	.4575	1.088	0.878-1.342	.48
≥1 FLG loss-of-function mutations	2.5237	1.242-5.10460	0.01	1.82	0.72-4.57 ns	.20
History of infantile eczema	2.75384	1.67244-4.48594	<.001	4.02554	2.14-7.54303	<.001
<u>Tree nut allergic reaction by age 8 years</u>	9.30	4.94-17.53	<.001	4.80	2.38-9.66	<.001
<u>Soya allergic reaction by age 8 years</u>	18.21	4.75-69.80	<.001	2.54	3.85-42.07	<.001
Egg sIgE sensitization at 4 years	7.66812	3.92435-14.95515	<.001	4.24664	1.98-9.09316 13.80	<.001
Allergic rhinitis aged 8 years (ISAAC)	4.02557	2.49357-6.52871	<.001	2.01305	1.0566-3.83563	0<.034 04

ns: Not significant on multivariate analysis therefore not included in final multivariate analysis.

Table V: Univariate analysis of factors associated with primary peanut ~~PAM~~ sensitization (at age 8 years) versus non primary peanut ~~PAM~~ sensitization (at age 8 years) in high risk children with preceding egg sensitization (at age 4 years) (n=134).

	Primary peanut PAM sensitization vs. non-peanut sensitized egg sensitized controls		
	OR	95% CI	P Value
EPE (µg/gram In transformed)	1.33	1.01-1.74	<0.05
Gender	1.90	0.95-3.80	0.07
Full older siblings	0.61	0.17-2.13	0.44
≥1 FLG loss-of-function mutations (excluding non-caucasians)	1.09	0.33-3.56	0.89
History of infantile eczema	2.51	1.24-5.08	0.01
<u>Localisation of infantile eczema (continuous 1-10 areas/per unit)</u>	<u>1.15</u>	<u>1.01-1.32</u>	<u>0.04</u>
<u>Localisation of infantile eczema (<5 areas vs. 5+ areas)</u>	<u>1.36</u>	<u>0.52-3.53</u>	<u>0.53</u>
<u>Application of topical steroids for itchy rash (1-2 yrs)</u>	<u>1.40</u>	<u>0.70-2.80</u>	<u>0.34</u>
<u>Persistent eczema at age 8 years</u>	<u>2.32</u>	<u>1.09-4.90</u>	<u>0.03</u>
<u>Allergic reaction to milk by 8 years</u>	<u>1.42</u>	<u>0.39-5.09</u>	<u>0.59</u>
<u>Allergic reaction to fish by 8 years</u>	<u>0.78</u>	<u>0.15-4.00</u>	<u>0.78</u>
<u>Allergic reaction to shellfish 8 years</u>	<u>0.30</u>	<u>0.06-1.58</u>	<u>0.16</u>
<u>Allergic reaction to wheat by 8 years</u>	<u>1.59</u>	<u>0.14-17.96</u>	<u>0.71</u>
<u>Allergic reaction to soya by 8 years</u>	<u>11.05</u>	<u>1.39-87.63</u>	<u>0.02</u>
<u>Allergic reaction to apple by 8 years</u>	<u>1.71</u>	<u>0.64-4.52</u>	<u>0.29</u>
<u>Allergic reaction to peach by 8 years</u>	<u>1.29</u>	<u>0.40-4.17</u>	<u>0.67</u>
<u>Allergic reaction to kiwi by 8 years</u>	<u>1.42</u>	<u>0.52-3.85</u>	<u>0.50</u>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

<u>Allergic reaction to avocado 8 years</u>	<u>0.78</u>	<u>0.11-5.71</u>	<u>0.81</u>
<u>Allergic reaction to banana 8 years</u>	<u>0.38</u>	<u>0.07-2.13</u>	<u>0.27</u>
<u>Allergic reaction to carrot by 8 years</u>	<u>2.36</u>	<u>0.71-7.85</u>	<u>0.16</u>
<u>Allergic reaction to tree nuts 8 years</u>	<u>3.43</u>	<u>1.54-7.62</u>	<u>0.002</u>
Allergic rhinitis aged 4 years (ISAAC)	0.87	0.38-1.96	0.73
Allergic rhinitis aged 8 years (ISAAC)	2.65	1.26-5.56	0.01
Parental atopy (asthma and /or hay-fever)	1.34	0.67-2.65	0.41
Non-caucasian ethnicity	2.55	0.93-6.98	0.07
Exclusively breastfed in months	0.89	0.77-1.04	0.14
Breastfed (exclusive/partial) in months	0.99	0.89-1.09	0.76
Maternal age at baseline (in years)	1.06	0.99-1.14	0.11

Peer Review

Legend

Figure 1: Mean predictive probability of peanut sensitization in children with primary peanut ~~PAM~~ sensitization (Ara h 1,2 or 3 ≥ 0.35 kU/L) versus children with peanut specific IgE ≥ 0.35 kU/L but with negative results for primary peanut ~~PAM~~ (Ara h 1,2 or 3 < 0.35 kU/L).

Contributions of each author

HB, IK, EH, MW, GL had substantial contributions to the conception and design of the study. HB, KM, MP and VR made substantial contributions to acquisition of peanut-dust data and analysis. HB and AD performed the statistical analysis of results. IK, EH, CS, AB, EM and MW had substantial contribution to the BAMSE study and obtaining data to perform this study. CS performed the FLG genotyping. All authors contributed to the drafting and revising the manuscript for intellectual content and have approved the version to be published.

Conflict of interests

H. A. Brough has received ~~research support from the National Peanut Board and has received~~ research support, lecture fees, and travel support from Thermo-Fisher Scientific. G. Lack and V. Turcanu have received research support from the National Peanut Board. I Kull, K Makinson, E Hallner, C Söderhäll, A Douiri, M Penagos, E Melén, A Bergström and M Wickman declare that they have no relevant conflicts of interest.

Comment [HB1]: Research funds went through Gideon Lack and Turcanu not Helen Brough

References

- Venter C, Hasan AS, Grundy J, Pereira B, Bernie CC, Voigt K, et al. Time trends in the prevalence of peanut allergy: three cohorts of children from the same geographical location in the UK. *Allergy* 2010; 65:103-8.
- Sicherer SH, Munoz-Furlong A, Godbold JH, Sampson HA. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. *J Allergy Clin Immunol* 2010; 125:1322-6.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3. Bock SA, Munoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. *J Allergy Clin Immunol* 2007; 119:1016-8.

4. Avery NJ, King RM, Knight S, Hourihane JOB. Assessment of quality of life in children with peanut allergy. *Pediatr Allergy Immunol* 2003;378-82.

5. King RM, Knibb RC, Hourihane JO. Impact of peanut allergy on quality of life, stress and anxiety in the family. *Allergy* 2009; 64:461-8.

6. Hourihane JOB, Kilburn SA, Dean P, Warner JO. Clinical characteristics of peanut allergy. *Clin Exp Allergy* 1997; 27:634-9.

7. Monti G, Muratore MC, Peltran A, Bonfante G, Silvestro L, Oggero R, et al. High incidence of adverse reactions to egg challenge on first known exposure in young atopic dermatitis children: predictive value of skin prick test and radioallergosorbent test to egg proteins. *Clin Exp Allergy* 2002; 32:1515-9.

8. Lack G, Fox D, Northstone K, Golding J, Team ALSoPaCS. Factors associated with the development of peanut allergy in childhood. *N Engl J Med* 2003; 348:977-85.

9. Strid J, Hourihane J, Kimber I, Callard R, Strobel S. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. *Eur J Immunol* 2004; 34:2100-9.

10. Reynolds LA, Finlay BB. Early life factors that affect allergy development. *Nat Rev Immunol* 2017.

11. Brough HA, Simpson A, Makinson K, Hankinson J, Brown S, Douiri A, et al. Peanut allergy: effect of environmental peanut exposure in children with filaggrin loss-of-function mutations. *J Allergy Clin Immunol* 2014; 134:867-75 e1.

12. Brough HA, Liu AH, Sicherer S, Makinson K, Douiri A, Brown SJ, et al. Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy. *J Allergy Clin Immunol* 2015; 135:164-70.

13. Fox AT, Sasieni P, Du Toit G, Syed H, Lack G. Household peanut consumption as a risk factor for the development of peanut allergy. *J Allergy Clin Immunol* 2009; 123:417-23.

14. Garcia-Boyano M, Pedrosa M, Quirce S, Boyano-Martinez T. Household almond and peanut consumption is related to the development of sensitization in young children. *J Allergy Clin Immunol* 2016; 137:1248-51.

15. Brough HA, Santos A, Makinson K, Penagos M, Stephens AC, Fox AT, et al. Peanut protein in household dust is related to household peanut consumption and is biologically active. *J Allergy Clin Immunol* 2013; 132:630-8.

16. Nicolaou N, Murray C, Belgrave D, Poorafshar M, Simpson A, Custovic A. Quantification of specific IgE to whole peanut extract and peanut components in prediction of peanut allergy. *J Allergy Clin Immunol* 2011; 127:684-5.

17. Dang TD, Tang M, Choo S, Licciardi PV, Koplin JJ, Martin PE, et al. Increasing the accuracy of peanut allergy diagnosis by using Ara h 2. *J Allergy Clin Immunol* 2012; 129:1056-63.
18. Asarnoj A, Ostblom E, Kull I, Lilja G, Pershagen G, Hedlin G, et al. Sensitization to inhalant allergens between 4 and 8 years of age is a dynamic process: Results from the BAMSE birth cohort. *Clin Exp Allergy* 2008;1507-13.
19. Asarnoj A, Ostblom E, Ahlstedt S, Hedlin G, Lilja G, van HM, et al. Reported symptoms to peanut between 4 and 8 years among children sensitized to peanut and birch pollen - results from the BAMSE birth cohort. *Allergy* 2010; 65:213-9.
20. Asarnoj A, Hamsten C, Lupinek C, Melen E, Andersson N, Anto JM, et al. Prediction of peanut allergy in adolescence by early childhood storage protein-specific IgE signatures: The BAMSE population-based birth cohort. *J Allergy Clin Immunol* 2017.
21. Wickman M, Kull I, Pershagen G, Nordvall SL. The BAMSE project: presentation of a prospective longitudinal birth cohort study. *Pediatr Allergy Immunol* 2002; 13:Suppl-3.
22. Bohme M, Lannero E, Wickman M, Nordvall SL, Wahlgren CF. Atopic dermatitis and concomitant disease patterns in children up to two years of age. *Acta Derm Venereol* 2002; 82:98-103.
23. Strachan D, Sibbald B, Weiland S, Ait-Khaled N, Anabwani G, Anderson HR, et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). *Pediatr Allergy Immunol* 1997; 8:161-76.
24. Brough HA, Makinson K, Penagos M, Maleki SJ, Cheng H, Stephens AC, et al. Distribution of peanut protein in the home environment. *J Allergy Clin Immunol* 2013; 132:623-9.
25. RW H, LD R. Estimation of average concentration in the presence of nondetectable values. *App Occup Environ Hyg* 1990; 5:46-51.
26. Baurecht H, Irvine AD, Novak N, Illig T, Buhler B, Ring J, et al. Toward a major risk factor for atopic eczema: Meta-analysis of filaggrin polymorphism data. *J Allergy Clin Immunol* 2007; 120:1406-12.
27. Weidinger S, O'Sullivan M, Illig T, Baurecht H, Depner M, Rodriguez E, et al. Filaggrin mutations, atopic eczema, hay fever, and asthma in children. *J Allergy Clin Immunol* 2008; 121:1203-9.
28. Hill DJ, Hosking CS, Oranje AP, Bauchau V, Naspitz CK, Simons FER, et al. Confirmation of the association between high levels of immunoglobulin E food sensitization and eczema in infancy: An international study. *Clin Exp Allergy* 2008; 38:161-8.
29. Brown SJ, Asai Y, Cordell HJ, Campbell LE, Zhao Y, Liao H, et al. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. *J Allergy Clin Immunol* 2011; 127:661-7.

Formatted: Font: (Default) Arial, Swedish (Sweden), Do not check spelling or grammar

Formatted: Swedish (Sweden)

Formatted: Font: (Default) Arial, Swedish (Sweden), Do not check spelling or grammar

Formatted: Font: (Default) Arial, Swedish (Sweden), Do not check spelling or grammar

Formatted: Swedish (Sweden)

Formatted: Font: (Default) Arial, Swedish (Sweden), Do not check spelling or grammar

Formatted: Font: (Default) Arial, Swedish (Sweden), Do not check spelling or grammar

Formatted: Swedish (Sweden)

Formatted: Font: (Default) Arial, Swedish (Sweden), Do not check spelling or grammar

1
2
3
4
5
6
7 636 30. Flohr C, Perkin M, Logan K, Marrs T, Radulovic S, Campbell LE, et al. Atopic dermatitis and
8 637 disease severity are the main risk factors for food sensitization in exclusively breastfed
9 638 infants. *J Invest Dermatol* 2014; 134:345-50.
10 639 31. Du Toit G, Roberts G, Sayre PH, Plaut M, Bahnson HT, Mitchell H, et al. Identifying infants
11 640 at high risk of peanut allergy: the Learning Early About Peanut Allergy (LEAP) screening
12 641 study. *J Allergy Clin Immunol* 2013; 131:135-43 e1-12.
13 642 32. Tariq SM, Matthews SM, Hakim EA, Arshad SH. Egg allergy in infancy predicts respiratory
14 643 allergic disease by 4 years of age. *Pediatric Allergy & Immunology* 2000; 11:162-7.
15 644 33. Gaffin JM, Sheehan WJ, Morrill J, Cinar M, Borrás Coughlin IM, Sawicki GS, et al. Tree nut
16 645 allergy, egg allergy, and asthma in children. *Clin Pediatr* 2011; 50:133-9.
17 646 34. Johansson EK, Bergstrom A, Kull I, Lind T, Soderhall C, van Hage M, et al. IgE sensitization
18 647 in relation to preschool eczema and filaggrin mutation. *J Allergy Clin Immunol* 2017.
19 648 35. Du Toit G, Katz Y, Sasieni P, Mesher D, Maleki SJ, Fisher HR, et al. Early consumption of
20 649 peanuts in infancy is associated with a low prevalence of peanut allergy. *J Allergy Clin*
21 650 *Immunol* 2008; 122:984-91.
22 651 36. Sicherer SH, Munoz-Furlong A, Sampson HA. Prevalence of peanut and tree nut allergy in
23 652 the United States determined by means of a random digit dial telephone survey: a 5-year
24 653 follow-up study. *J Allergy Clin Immunol* 2003; 112:1203-7.
25 654 37. Sampson HA, McCaskill CC. Food hypersensitivity and atopic dermatitis: evaluation of 113
26 655 patients. *J Pediatr* 1985; 107:669-75.
27 656 38. Nicolaou N, Poorafshar M, Murray C, Simpson A, Winell H, Kerry G, et al. Allergy or
28 657 tolerance in children sensitized to peanut: prevalence and differentiation using component-
29 658 resolved diagnostics. *J Allergy Clin Immunol* 2010; 125:191-7.
30 659 39. Beyer K, Grabenhenrich L, Hartl M, Beder A, Kalb B, Ziegert M, et al. Predictive values of
31 660 component-specific IgE for the outcome of peanut and hazelnut food challenges in children.
32 661 *Allergy* 2015; 70:90-8.
33 662 40. Besharat PM, Bergstrom A, Bottai M, Kull I, Wickman M, Hakansson N, et al. Effect of
34 663 parental migration background on childhood nutrition, physical activity, and body mass
35 664 index. *J Obesity* 2014; 2014:406529.
36 665
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Formatted: Font: (Default) Arial, Swedish (Sweden), Do not check spelling or grammar

Formatted: Font: (Default) Arial, Swedish (Sweden), Do not check spelling or grammar

Formatted: Swedish (Sweden)

Formatted: Font: (Default) Arial, Swedish (Sweden), Do not check spelling or grammar

Predictive probability of peanut sensitization

----- No primary peanut sensitization

———— Primary peanut sensitization